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This term is used to describe a plasma
protein which releases a kinin with properties
like bradykinin during incubation with trypsin*
"Kininogen" and "bradykinin precursor" are
used as synonyms.
Unit
One unit of bradykininogen is the quantity
which releases the equivalent of one j
synthetic bra&ykinin.
When one mg of protein releases kinin
equivalent to x ug bradykinin, the preparation
is said to have a specific activity of x ug
bradykinin per mg of protein. One mg of this
protein contains x ug. "potential bradykinin".
INTRODUCTION
The aim of the work now described has been
the isolation from human plasma of the protein
precursor of bradykinln. This is an essential
preliminary to the characterisation of the
protein and to the study of kinin-forraing
enzymes under controlled conditions.
The purification procedure has been
designed to satisfy the following criteria
as completely as possible.
1) The purified bradykinin precursor shall be
free from kinin-forming enzymes and antagonists
of these enzymes and also from kinin-destroying
enzymes (kininsses).
2) Conditions which carry a risk of
denaturatlon shall be avoided.
3) The purified protein shall retain its
biological activity under convenient storage
conditions for long periods.
h) A high proportion of the kinin precursor
present in fresh plasma shall be recovered.
5) The quantity of purified bradykininogen
shall be adequate for the detailed study of
activation by several enzyme systems and for
the preliminary characterisation of the
protein.
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6) The final product shall he homogeneous as
judged by
a) protein fractionation procedures with a
high degree of resolution*
b) measurements of specific biological
activity (ug bradykinin per rag protein)*
Before describing the development of the method,





properties released from plasma proteins have
"been termed plasma kinins. (Lewis, 1958)*
Recently five human plasma kinins have "been
distinguished by paper electrophoresis and
chromatography, (Armstrong and Mills 1963)*
One of the group may be identical with the new




H-Arg. Pro. Pro. Gly. Phe. Ser. Pro. Phe. Arg-QH.
Pure bradykinin (Bk) formed by the action
of trypsin on acid-treated ox pseudoglobulin was
isolated by Elliot, Lewis and Horton (i960 a.)
after ethanol extraction, counter current
distribution, chromatography on CM-cellulose
and preparative paper electrophoresis. The
same workers established the amino acid
composition and sequence, (Elliot, Lewis and
Horton i960 b.)
Synthesis was achieved by Boissonas and
his co-workers. The synthetic peptide was
identical in biological activity with pure
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ox bradykinin. (Boissonas, Guttmann and
Jaquenoud i960 (a) and (b)j Boisaonas, Guttmann,
Jaquenoud, Konzett and Sturmer, 1960)#
The molecular weight of the dihydrochloride




When acid-treated human plasma was
incubated with human urinary kallikrein
(Pierce and Webster 1961) two plasma kinins
were formed — kallidin I and II. Kallidin I
was identical with bradykininj kallidin II
differed by the addition of lysine in the
N-terminal position.
Bradykinin and lysylbradykinin were also
formed by the action of bovine salivary
kallikrein on plasma (Werle, Trautschold and
Leysarth, 1961).
Lysylbradykinin was synthesised by
Nicolaide^, De Wald and McCarthy (1961).
Methionyllyaylbradykinin
H~Meth.Lys.Arg.Pro.Pro.Gly.Fhe.Ser.Pro.Phe,Arg-OH
Acid-treated ox pseudoglobulin at pH 7.5
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released bradykinin, lysylbradykinin and a
third kinin. Elliot, Lewie and Smyth (1963)
isolated the latter and identified it as
methiony1 lysylbradyk inin.
Other plasma kinina
The euglobulin fraction of human plasm©
precipitated by 33$ saturation with ammonium
sulphate, formed kinins F and S spontaneously
on incubation. They were separated and
distinguished from bradykinin and
lysylbradykinin by paper chromatography in
butanol : acetic acid : water (U : 1 : 5) and
butanol j pyridine: water (l : 1 : l).
A kinin-forming enzyme from the
euglobulin fraction acted on fresh plasm© to
form kinin E, (Armstrong and Mills, 1963).
One of the kinins E, F and S may be
identical with methionyllysylbradykinin.
2. tewm
The plasma kinins stimulate certain smooth
muscles, produce vasodilatation, increase
capillary permeability, cause chemotaxis of
leucocytes and evoke pain from an exposed
blister base.
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The pharmacological actions of pure
natural bradykinin were described by Elliot,
Horton and Lewis (i960). The information
summarised below was taken from these authors
except where other references are given.
AfrtflPhs 9,n, ftpuw.th «ypcie
The isolated guinea-pig ileum gave the
characteristic alow contraction with 10~® M
bradykinin whereas the uterus of the
stilboestrol treated rat responded to lo""1 0 M
bradykinin. The dose response curve of the
rat uterus was often very steep) a twofold
increase in concentration could convert a
threshold response into a maximum contraction.
Certain smooth muscles which showed
rhythmic activity and a high resting tone
were inhibited by bradykinin. The rabbit
duodenum and the rat colon showed inhibition
followed by stimulation. The rat duodenum
showed only relaxation at a concentration of
3. 10~* M.
The intravenous injection of 0.5 ug pure
bradykinin in the anaesthetised guinea-pig
caused bronchoconstriction comparable to that
caused by 0.5 ug histamine, Bronchoconstriction
was demonstrated by the method of Konzett
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and Rossler (l9h0). A series of injections
repeated at intervals of less than 10 minutes
produced loss of sensitivity to bradykinin.
The bronchoconstrietor effects of
bradykinin were antagonised "by acetylsalicylic
acid, phenylbutazone, amldopyrine, mefenamie
acid and flufenamic acid at concentrations
which did not affect the response to histamine
or 5-hydroxytryptamine. (Collier and Shorley,
1960j Collier, 1963* Collier and Shorley,
1963).
Most normal men were unaffected by
aerosols of 2% bradykinin in saline whereas
13 out of 15 asthmatic subjects developed
dyspnoea and a 10 - 3Cg£ reduction of vital
capacity with bradykinin. (Herxheimer and
Stresemann, I96I). Isolated rings of bronchial
muscle were relatively insensitive to
bradykinin.
Increased capillary permeability
The intradermal injection of bradykinin in
the guinea pig after intravenous Fontamine sky
blue produced intense local blueing. Elliot,
Horton and Lewis showed that on a molar basis
pure bradykinin was about 15 times as active as
histamine. There were however qualitative
8
differences between the responses to the two
agents.
100 ng bradykinin produced en increase in
flow through the cat hind limb in vivo
comparable to that produced by 10 - 20 ng
acetyl choline.
Intravenous bradykinin lowered mean
anterlal pressure in the anaesthetised cat
(hOO ngAg) rat (150 ng/lOOg).
Stimulation of pain fibres
Bradykinin (lO-7 - IO^m) evoked transient
pain from the base of a blister without the
itching, flare and wheal which had been
observed with crude plasma kinins. (Armstrong,
Jepson, Keele and Stewart, 1957)• vvhen the
concentration was increased 10-fold pain lasted
for 2-3 minutes. After repeated doses of
bradykinin higher concentrations were needed to
evoke a comparable response. The desensitised
area was unchanged in its sensitivity to
histamine or 5-hydroxytryptamine.
The effects described above had all been
observed previously with impure plasma kinins
(Rocha e Silva 1955* Werle i960, Roche e Silva
9
I960, Lahiri 1962, Lewis i960),
Lysylbradykinln and methiony1lysylbradyXinin
have the same actions as bradykininj there are
however quantitative differences between the
three kinlns (Table l). Pull reports of the


































References (a) Webster and Pierce, 1963.
(b) Nicolaides, De Weld and Craft, 1963,
(c) Elliot, Lewie and Smyth, 1963,
(d) Habermann, 1963*
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Rocha e Silva, Beraldo and Rosenfeld (I9I+9)
described the release of bradyklnin from dog and
ox plasma "by trypsin and venoms from the genus
Bothrops. The precursor of bradykinin was
precipitated from plasma when the concentration
of ammonium sulphate was increased from 30 to
k5% saturation. This fraction, the classical
pseudoglobulin, contained all the protein
components of blood plasma but with relatively
small quantities of albumin and Y-glo"bulin.
(Lewis 1960).
For several years plasma pseudoglobulin was
used as the substrate for the study of kinin¬
forming enzymes. (Beraldo, I950j Rocha e
Silva, 1951* Hilton and Lewis, 19!>6; Hilton
and Fox, 1956* Lewis, 1958). The
pseudoglobulin from untreated serum or plasma
contained both kinln-forming and destroying
enzymes. Inactlvation of these was achieved by
heating the serum for 3 hours at 56°. This
practice was introduced by fterle, Gotze and
Keppler (1937) as a method of inactivating serum
kallikrein. During the heating a large part
of the kinin precursor was lost however.
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A further modification was introduced by
Horton (l959)« bog plasma was brought to pH 2
by the addition of IN HC1 and incubated at 37°
for 10 minutes. IN NaHC03 was then added and
pll 7.3 restored. Acid-treated dog plasma was
free from kininase and virtually free from
kallikrein. Horse plasma treated in this way
contained active kallikrein however (Henriques,
Picarelli and Ferraz de Oliveira, I962).
Van Arman (1952) studied the bradykininogen
content of bovine plasma fractions prepared by
Cohn method 10. The bradykinin precursor was
found in fraction IV and sub-fraction h
contained twice as much potential bradykinin as
sub-fraction 1. Bovine IV - k and human IV - 1
both contain kininase (Henriques et al, 1962,
ErdSe and Bloane 1962). Amongst the
sub-fractions of bovine IV - Uf IV - 6 was
most rich in bradykinogen (Van Arman 1955)
but this fraction contained both kininase and
kallikrein (Habermenn, 1963).
During the paper electrophoresis of human
plasma the plasma kinin precursor migrated as
an oa globulin (werle 1955)•
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Denatured bradykininogen remained
vulnerable to trypsin; it was however resistant
to the action of kallikrein (Dinlz and
Carvalho, 1963; Habermann, 1963). The two
most recently introduced methods for the
estimation of bradykininogen in whole plasma
depend upon the quantitative release of
bradykinin from denatured substrates by
crystalline trypsin* The first of these was
described by Diniz, Carvalho, Ryan and Rocha e
Silva, 1961. Venous blood was taken in a
siliconed syringe containing heparin. After
centrifugation in polythene or siliconed glass,
0,2 ml plasma was added to 1.8 ml. 0.25? acetic
acid and heated at 100° for 30 minutes. The
denatured protein suspension was then
neutralised with N NaOH and 0,5 ml. 0,211.
Trie buffer (pH 7»8) was added. After
incubation with trypsin (200 ug/ml.) the
bradykinin released was extracted with ethanol
and assayed on an Isolated smooth muscle
preparation against standard bradykinin. 1 ml.
human plasma contained potential kinln
equivalent to ~?*k - lk,2 ug bradykinin.
A second method for the estimation of
bradykininogen in heparin treated plasma was
described (Brocklehurst and Lahiri 1962,
Lahlri 1962). Protein precipitation in 805'
IU
ethanol, at 0° was followed "by heating at
80-90° for 20 minutes. The washed precipitate
was incubated for 20 minutes with trypsin
(500 ug/ul) in 0.1 M sodium phosphate buffer
at pH 7.U. The trypsin was inactivated by
heating and the kinin concentration determined
by bioassay. Guinea pig plasma contained
kinin precursor equivalent to 12.8 - 1.9 ug
bradykinin per ml.
In October 1961 when the work described
in this thesis was started the information
available about the bradykinin precursor
was that summarised above. During the last
two years four groups have published procedures
for the purification of the bradykinin
precursor, from horse plasma (Hcnriques,
Plcarelli, and Perraz de Olivelra, 1962),
from bovine plasma (Habermann and Hosenbusch
I962, Greenbaum and Hosoda 1963) and from human
plasma (Webster and Pierce I963). None of
these methods fully satisfies the criteria set
out in the introduction to this thesis.
Henriques et al treated oxalated horse
plasma by the method of Horton (1959)* The
precursor was protected from the action of the
activated endogenous kinin-forming enzyme by
20% saturation with ammonium sulphate.
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The supernatant was fractionated "by
precipitation at 33 and 5C$ saturation# l#7g
of the precipitate at 50^ saturation was
dissolved in physiological saline, dialysed
against 0#005 M sodium phosphate buffer,
pH 7»0 and applied to a column of DEAE-cellulose
(2xh0 cm).
During gradient elution the bradykinin
precursor left the column in 0.08 M sodium
phosphate buffer 0#16 M with respect to NaCl#
The active fractions were applied to a second
DEAE column (l.l x 38 era) and gradient elution
repeated# The final product contained 3^"
of the bradykinin precursor originally present
in the acid-treated plasma and 0,2% of the
original protein# lmg of this protein gave the
equivalent of 3.14 ug bradykinin with trypsin
and 5.0 ug with the partially purified kinin-
formlng enzyme from the venom of Bothrops
Jararaca#
The bradykininogen is purified 170 fold by
the method of Henriques et al# Acid-treatment
carries a serious risk of denaturation however;
the product may have different characteristics
from the native protein. Protein estimations
were made by a sensitive colorimetric method
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(Lowry, Rosenbrough, Farr and Randall, 1951)
which requires a standard protein for
calibration. The authors do not state which
protein was used so that direct comparison with
the results of other workers is not possible.
The yield of bradykininogen compares well with
other methods. The product was said to be
free from kinin forming enzyme and assumed to
be free from kininase but no adequate data
were given to support this. The heterogeneity
of the purified protein was apparently not
investigated,
Habermann and Roseribueeh (1962) applied
Cohn method 6 to bovine plasma. They
recovered about 8Q£ of the total bradykininogen
in fraction IV, Subfractionation gave most of
this in fraction IV-6. This fraction was
submitted to chromatography on calcium
hydroxylapatite at pH 5,2 in acetate-phosphate
buffer and eluted by continuous increase in
ionic strength. The preparation released kinin
with trypsin, Crotalus adamanteus venom and a
kallikrein from pig pancreas. The kininogen
was free from kinin forming enzyme but
contained kininase, 1 mg of purified protein
gave the equivalent of 10 - 20 ug bradykinin
with trypsin.
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Cohn fractionation appears to produce
some denaturetionj van Aman (1952) found that
IV - 4 contained much insoluble protein,
Habenaann (1963) did not comment on the
heterogeneity of the product nor did he state
the method used for protein estimation,
Greehbaum and Hosoda (1963) developed a
purification procedure for bovine bradykininogen
which depended upon the persistent solubility
of the protein at 100° in the presence of Ca**,
Bovine blood was defibrinated by whipping and
~lKts »
then^heated at 57«5° for 3 hours to inactivate
peptidases. The serum was dialysed and
ammonium sulphate added to 5Q& saturation.
The serum globulin was dissolved in water,
dialysed and heated in a boiling water bath.
In the presence of calcium ion and Tria
buffer at pH 7,7 a large amount of " inactive
protein" precipitated as a coagulum. After
centrifugation the supernatant was dialysed
against 0,001 M sodium ethylenediamlnetetra¬
acetate (EDTA) to remove Ca++, Precipitation
of bradykininogen took place when the pH was
brought to 5»3* After repeated precipitation
the bradykininogen was obtained as an acetone-
dried powder.
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The data given do not make it possible
to calculate the overall recovery# The method
gives less than 3$ of the bradykinin precursor
present in the crude globulin fraction however#
1 mg of the purified protein gave kinin
equivalent to 0#8 - 1*0 ug bradykinin after
incubation with trypsin. Free boundary
electrophoresis at pH 8,6 and 7.5 gave one peak.
The method described by Greenbaum and
Hosoda has the advantage that it can be applied
to large volumes of blood. This is offset by
the very low yield and furthermore the specific
activity of the product is only one tenth of
value given by Habermann et al# Free boundary
electrophoresis gives poor resolution when
compared with starch gel or Immunoelectrophoresis
and the low specific activity is evidence of
heterogeneity* greater resolution might have
been obtained by the use of pH values on different
sides of the isoelectric point. The main
disadvantage is the use of very extreme physical
conditions which invite denaturation.
Webster and Pierce (1963) developed a
method for the purification of the human klnin
precursor from out-dated acid-citrate-dextrose
plasma. Diluted plasma was adjusted to pH 6.0
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and stirred with DBAS*cellulose at 18 - 20°C.
This was filtered and the kinin precursor eluted
in 0.3 M. potassium phosphate "buffer pH 6.0.
After dialysis and centrifugation the protein
was added to e column of DRAE-cellulose
(k»3 x 38 cm.) from which elution took place
with a series of potassium phosphate buffers of
increasing ionic strength* the kininogen was
eluted by 0,12 M buffer. The active fractions
were concentrated and applied to a column of
hydroxylapatite (3.6 x 2k cm.) previously
equilibrated with dilute potassium phosphate
buffer, pi! 6.8. Elution was again achieved by
stepwise increase in potassium phosphate
concentration. The main part of the kinin
precursor was eluted at 0.039 M. lf$ of the
kininogen was recovered with 150-fold
purification. However only remained after
dialysis, filtration and freeze drying.
The use of outdated plasma was unfortunate,
since human plasma loses more than 7g& of its
kininogen over k days at k° (Webster and
Pierce, i960). The loss of biological activity
on final concentration may be due to leakage of
kininogen through dialysis sacs or to the
presence of kinin-forming enzyme.
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In all species investigated the plasma kinin
precursor is an as globulin. The kininogen from
bovine serum may have an isoelectric point of
5*3« There is no published information about
molecular weight or the number of molecules of
potential kinin present in one protein molecule,
Bradykinin, lysylbradykinin and
laethionyllysylbradykinin may be derived from the
same protein molecule* the bradykinin sequence
is common to all three kinins. The purest
preparations of kininogen release bradykinin or
lysylbradykinin with different kinin-forraing
enzymes (Habermann, I9631 Webster and Pierce,
1963), The substrate for kallikrein is
exhausted by prior incubation with trypsin and
vice versa (Habermann 1963)#
The link between the polypeptides and the
rest of the protein molecule may be via an
ester linkage. Four possibilities were
suggested by Elliot (1963)*
1) An ester linkage between C-terminal Arginine
and a carbohydrate part of the main protein,
2) An ester linkage between the - OH grouping of
serine and a C-terminal arginine or lysine
in the main protein.
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3) An ester linkage "between C-terainal Arginine
and. the -OH group of a serine component of the
main protein.
k) A peptide linkage to the rest of the protein
molecule.
Hamberg and Rocha e Silva (1957) showed
that when snake venom was heated the bradyklnin-
releasing activity and the esterol~tic activity
on benzoyl-arginine methyl ester decreased
slowly in parallel whereas proteolytic
activity towards casein was lost much more
rapidly. This suggests that kinin release
depends on the hydrolysis of an ester bond.
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ENZYMES WHICH RELEASE
PLASMA K I N I N S
The early work on the enzymes which release
plesraa kinins has "been extensively reviewed
(Prey, Kraut and Werle 1950, Werle 1955» I960,
Lehiri, 1962) and this section deals mainly with
recent advances,
wms.
When trypsin acted on pseudoglobulin only
bradykinin was detected although lysylbradykinin
may have been formed as an intermediate,
(Elliot, Lewis and Horton i960 (a) and (b) ),
Trypsin (20 fig/ml) released all the
bradykinin from purified kininogen (10 mg/ml)
in 120 minutes at 37° (0.10 M Tris buffer,
pH 7*8, 0,2 M CaCla was used for the incubation).
An inverted exponential type of curve related
kinin release to time (Oreenbaum and Hosoda,
1963).
Diniz and Carvalho (1963) determined the
optimum conditions for the release of bradykinin
from denatured kininogen. The potential kinin
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in 0.2 ml. plasma was completely released by
trypsin (200 ug/fel) in 30 minutes at pH 7*8 and
37°• The enzyme was more active at this pH than
at 7.U or 8.2.
This term was used by Prey and Kraut
(1928) to identify an agent in urine which caused
hypotension on intravenous infection. Urinary
kallikrein was later shown to act by the
release of kinin. Several different enzymes
with this action have now been demonstrated in
tissue fluids and extracts of exocrine glands.
Highly purified kallikreins have been
prepared from the following sources* pig
pancreas (llabermann, 19631 Moriya, Pierce and
Webster, 1963* Werle and Trautschold, 1963)1
pig salivary gland, urine and serum (Werle
and Trautschold, 1963)* horse urine (Frado,
Prado, Brandi and Katchburian, 1963)* bovine
pancreas (Webster, Clark and Anderson 1956)*
human plasma, pancreas and urine (Webster and
Pierce, 1963* Moriya, Pierce and Webster,
1963).
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Human kallikreins obtained from different
sources differed in physical properties,
immunological properties, enzyme activity and
sensitivity to inhibitors#
Purified kallikreins from human urine and
pancreas had molecular weights of 1+0,500 and
31»200 respectively* the urinary kallikrein
migrated more rapidly than the pancreatic enzyme
during electrophoresis in Cyanogum gel
(Moriya et al, 1963)#
A rabbit antiserum to crude human urinary
kallikrein inhibited the vasodilatation produced
in the dog by pure human urinary kallikrein*
the response to pure human pancreatic kallikrein
was also inhibited. In agar gel the antiserum
gave single, precipitin lines with the pure
kallikreins from urine and pancreas. These
two lines became continuous. No comparable
line was given by human serum and there was no
cross reaction with kallikreins from dog urine
or pig pancreas (Webster, Emmant, Turner,
Moriya and Pierce, 1963).
Kallikrein from human urine released only
lysylbradykinin from purified human kininogen
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whereas human plasma kallikrein released only
bradykinin# Neither enzyme produced bradykinin
from synthetic lysylbredykinin ("Webster and
Fierce, 1963)# Human and pig pancreatic
kallikrein and pig salivary gland kallikrein
resembled human urinary kallikrein (Webster and
Pierce, 1963; Werle, Trautschold and Leysarth,
1961),
Crude kallikrein preparations were
proteolytic but highly purified kallikreins from
pig pancreas, pig salivary gland and human
urine had negligable proteolytic activity on
casein or haemoglobin# These enzymes had
esterolytic activity however which was strictly
limited to certain esters of benzoyl-L-arginine
and p-tosylarglnine. The hydrolysis of
benzoylarginlne ethyl ester (BAEE) was used for
the measurement of kallikrein activity (Werle and
Trautschold, 1963).
Purified pig serum kallikrein retained both
proteolytic and fibrinolytic activity# Werle
and Trautschold suggested that the preparation
was contaminated with plasmin# The kallikrein
of serum or plasma may however be able to
hydrolyse a range of both ester and peptide links.
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The selective inhibition of kallikreins
from different sources is described in the
section on kallikrein inactivatora.
When acid-treated ox pseudoglobulin was
incubated at pH 7.5 in the absence of exogenous
enzyme, bradykinin and lysylbradykinin
(Haberraann and Okon, 1961; Elliot, 1963) and
methionyllysylbradyklnin (Elliot et al, 1963)
were formed. One or more kinin-forming enzymes
had been activated.
Human plasma euglobulin (precipitated at
33$ ammonium sulphate saturation) formed
plasma kinins F and S spontaneously. A kinin-
forming enzyme purified from this fraction
released kinin E from fresh plasma (Armstrong
and Mills, I963K This enzyme was inhibited
by hexadimethrine bromide but not by £ -amino-n-
caproic acid (Armstrong and Mills, 1962); it
may differ from both plasma kallikrein and plasmin.
THE ACTiYATSW 0?' ftAMEFEtPOgSW
The kallikreins of plasma and pancreas occur
as inactive precursors. Activation of plasma
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kallikreinogen has been described after the
following treatments* acidification of serum
with HC1 to pH 2.0 at 0° (Kraut, Frey and Vi/erle,
1933)* incubation of horse plasma at pH 2.0
and 37° for 15 minutes (Henriques et al, 1962)*
incubation with trypsin or papain (Werle 1955)*
exposure of serum to 2C$> acetone for h hours
(Webster and Pierce, i960)* treatment with
acetophenone or benzophenone (Frey, Kraut and
Werle, I950)} treatment with chloroform
(Lewis 1958).
Pancreatic kallikreinogen was extracted
from pancreatic tissue in which autolysis had
been suppressed. This proenzyme was activated
by trypsin. Similar proenzymes were obtained
from brain and intestine (Werle* i960).
The active sites of these kinin-forming
proenzymes may be masked by additional groups
which dissociate at low pH and in the presence
of certain organic solvents. In other
situations the masking groups may be removed
by hydrolytic enzymes such as plasmin or trypsin.
It is possible that the final step in the
activation of plasma kallikreinogen is always
enzymic, although a variety of physical conditions
initiate the process.
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The kallikreinogens of plasma and pancreas
could "be activated normally after incubation with
DPP and removal of the excess* The
corresponding kallikreins lost their hypotensive,
kinin-forraing and esterolytic activity however
in the presence of DPP. These inactivated
kallikreins no longer "bound the naturally
occurring inactivators described in the next
section* It was suggested that a serine unit
was present in the active 3lte of the enzyme and
that this was essential for kinin-forming activity
and combination with the masking group or
lnactivator (Werle and Trautschold, 1963).
KALLIKRKIN INACTIVATORS
Werle and Trautschold (1963) described two
kallikrein Inactivators in serum which could be
distinguished by their pH optima and
solubilities in perchloric acid. Other
inactivators occurred in extracts of parotid
salivary gland, liver, lymph gland, posterior
pituitary, potatoes and egg white. Some non¬
specific antagonists of proteolytic enzymes*
others were polypeptides with a high specificity
for the kallikreins (Werle, 1955).
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Many kallikreins were inhibited by
incubation with DFP (Habermann, 1960} Werle
and Trautschold, 1963)* Webster and Pierce
(1963) described the pattern of inhibition of
purified human kallikreins. Soya bean trypsin
inhibitor (SBTl) was effective only against
plasma kallikrein and egg white against urinary
kallikreinj kallikreins from plasma, pancreas
and urine were all inhibited by pancreatic
trypsin inhibitor (PTl) but unaffected by ovomucoid
trypsin inhibitor (OTl).
Several analgesic-antipyretic drugs inhibit
kinin-formation in vitro. Phenylbutazone,
2:6 dihydroxybenzoic acid, sodium a(U-sec-
butylphenoxy) propionate, salicylate and acetyl-
salicylate inhibited the kallikreins of guinea-
pig serum and human saliva at concentrations
which did not interfere with the bioassay of
kinins (Northover and Subramanian, I96I),
mm
Two plasminogens, designated A and B, have
been detected in human plasma by Immuno¬
electrophoresis in fibrin-agar plates (kybak and
Petakova, 1963). These plasminogens have no
proteolytic activity! activation is essential
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before the proteolytic properties of plasmin
appear#
Plasmin hydrolyses fibrin, fibrinogen, casein,
haemoglobin, toeylarginine methyl ester (TAME)
and lysine ethyl ester (Sherry, Fletcher and
Alkjaersig, 1939)* The enzyme is inhibited by
DFP (Mounter and Shipley, 1953), an antlplasmin
from Cohn IV-l (Siegel, Barclay and Cliffton,
1956), several trypsin inhibitors and
g-aminocaproic acid (Alkjaersig, Fletcher and
Sherry, 1959)•
A large number of agent® activate plasminogen;
plasmin itself (Mounter and Shipley, I95Q)*
trypsin, urokinase, streptokinase (Alkjacrsig,
Fletcher and Sherry, 1958); enzy; ^s in blood,
skin and lung* chloroformi silica surfaces*
ammonium sulphate# This subject has been
reviewed by Sherry et al, (l959)« Many of
these agents also activate plasma kallikreinogen#
The release of plasma kinin by plasmin was
first described by Beraldo (1950). Human
plasmin released kinin from dog pseudoglobulin
(Lewis and Work, 1957; Lewis, 1958) and
preactive human plasma (Bisen, I961)# This
was prevented by an antiplasmin and by 8BTI
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(Lewis, 1958} Schachter, i960).
Intravenous plasmin lowered arterial blood
pressure in several species including man
(Back, Guth, and Munson, I963). Tachyphylaxis
developed! Back et al showed that this was not
due to depletion of kininogen.
Eisen (1963a) compared the relative effects of
different activating treatments on the
fibrinolytic and kinin-forming systems of human
plasma. Silica surfaces, acidification and
acetone precipitation produced rapid release of
kirin with low rates of fibrinolysis. Ammonium
sulphate precipitation and streptokinase
favoured fibrinolysis rather than kinin formation*
€-aminoeaproic acid ~id not prevent the
development of kinin-forraing activity in plasma
exposed to glass (Armstrong and Stewart, i960),
low pH, acetone or chloroform (Eisen, 1963).
Eisen concluded that the kinin-forming system
of plasma was probably independent of the
fibrinolytic system.
Using kailikrein-free human plasmin Vogt
(1963) observed kinin release from unheated dog
plasma globulin but not from heated globulin
(56° for 2 hours) or purified bovine kininogen.
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He concluded that plasmin released kinin
indirectly by the activation of plasma
kal1ikreinogen.
sokfacb activation of plasma kinins 0 c c7„
When plasma was brought into contact with
glass, klnin was released (Armstrong, Jepson,
Keele and Stewart, 1957)♦ Tbe complex sequence
of reactions responsible has been studied in
detail^(Keele I960, Kisen 1963(a), Margolis 1963).
On exposure of plasma to negatively charged
surfaces (glass, kaolin, alumina and others)
Hageman Factor was adsorbed and the physical
state of this basic protein altered so that it
became capable of activating component A.
Activated component A released kinin from its
precursor in the presence of an essential
cofactor (Component b). (Keele i960,
Margolis 1963),
Activated Hageman Factor may be responsible
for the initiation of blood clotting and
fibrinolysis.
The nature of components A and b is not well
established. The actions of component A were
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prevented by heating at 56° for 2 hours and by
SBTI, and it may be identical with plasma
kallikrein (Eisen 1963a). Plasma could be
depleted of component B under the action of
activated component A (Keele i960).
9? IWMA Kirons ]3Y D^^tfTIoy
The release of kinin on dilution of plasma
or serum was described by Schachter (1956). The
optimum dilution, the quantity of bradykinin-
like activity detected and the rate of
inactivation varied with the species.
Dilution appeared to activate endogenous
kinln forming enzymes and to reduce the
effectiveness of the plasma kallikrein
inactivators. Eisen (1961) reported that both
glass activation and dilution activation were
due to the same enzyme.
ONAKE VENOMS
The kinin-forming enzyme from Bothrops
jararaca was purified by selective denaturation
and ammonium sulphate fractionation. Proteolytic
activity decreased during purification (Henriques,
Ficarelli and Oliveira 1962),
3k
Venoms from Agkistrodon contortrix and
piscivorus (Webster and Pierce, I963) and
Crotalus adamanteus (Habermann 1963) released





The plasma kinins are hydrolysed by
several proteolytic enzymes! biological
activity is usually reduced or abolished.
mmm
Trypsin hydrolysed peptide or ester links
formed from the carboxyl groups of L-arginine or
L-lysine. When other amino acids replaced
arginine or lysine in synthetic substrates the
peptide became resistant to trypsin.
(Bergmann and Fruton, l9Uli Dixon and ftebb,
1956a).
Trypsin acted on methionyllysylbradykinin
and lysylbradykinin to give bradykinin (Elliot,
Lewie and Smyth, l9^3i Erdos, Rendrew, Sloane
and VVohler, 1963; Nicolaides, Deftaid and
Craft, 1963). Bradykinin itself was stable
in the presence of trypsin (Rocha e Silva, 1955)
unless the concentration was high (Diniz and
jCarvalho, 1963)* Inactivation by high
concentrations of trypsin was probably due to
contamination with carboxypeptidase or
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chymotrypsin (Desneuelle and Rovery, 1961).
The atypical imlno acid proline probably
protected the N-terrainal exopeptide bond from
hydrolysis by trypsin.
SHYMQTiOTSiff
Chymotrypsin hydrolysed peptide or ester
linkages formed from the carboxyl groups of
phenylalanine or tyrosine (Bergmann and Fruton,
1941)} in its presence bradykinin lost its
biological activity (Rocha e Silva, 1955) end
was split into three parts. These were
identified as arginylprolylprolylglycylphenyl-
alanlne, serylprolylphenylalanine and arginine
(Elliot, Lewis and Horton, i960 b).
c/fffiOTpKPyi PASS f?
The basic carboxypeptidase inactivated
bradykinin and lysylbradyklnin (Erdos, Renfrew,
Sloane and Wohler, 1963). The enzyme was
specific for an exopeptide bond involving a C
terminal arginine or lysine unit (Polk and
Gladner, 1958 8 and b); it may be responsible
for the kininolytic activity of commercial
preparations of pancreatic kallikrein. The loss
of biological activity on exposure to pure
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carboxypeptidase B confirms that the
activity was due to a bradykinin-like peptide.
Low concentrations of chymotrypsin and
carboxypeptidase B had identical effects on the
bradykinin molecule. Chymotrypsin however
inactivated most biologically active peptides,
(Gaddum, 1955).
PLASMA KININASE
Plasma fractions which contained bradykinin-
ogen commonly contained kininase (Werle 1955J
Lewis i960* Henriques, Picarelli and Perraz de
Oliveira 1962j Habermann I963).
Horton (1959) demonstrated that the kininase
of dog plasma was inactivated by incubation at
pH2 and 37° for 20 minutes.
Kininase activity was found in the Cohn IV-1
fraction of human plasma (Erdos, and Bloane, 1962j
Erdos, Kenfrew, Sloane and Wohler, 1963). The
fraction behaved as a carboxypeptidase splitting
off the C-terminal arginine from synthetic
bradykinin or lysylbradykinin. The kininase was
distinguished from pancreatic carboxypeptidase B
however by the different susceptibilities of the
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two enzymes to inhibitors (Table II )• Erdos
et al called the enzyme "carboxypeptidase-N",
When the carboxypeptidase of human plasma
had been inhibited by manganese ions, additional
proteolytic activity was demonstrated* the
N-terminal peptide bond of lysylbradykinin was
split by an aminopeptidase (Erdoe et al, 1963).
m vm ppgYMsg
During incubation with lysed red cells,
synthetic bradykinin was split into its amino
acid components and the arginine units were
converted to ornithine (ErdSs et al, 1963).
Bradykininolytic enzymes have been reported
in preparations from kidney and liver (Hamberg
and Roche e Silva 195^4* Werle 1955 )•
Brocklehurst and Lahiri (1962) described a
klninase released during perfusion of guinea
pig lung with Tyrode solution. The rate of
release was uninfluenced by an antigen-antibody
reaction. Activity was lost in 30 minutes at
56° But SBTI had no effect. The optimum pH for
the inactivation of synthetic bradykinin lay
between 7,0 and 7,5,
TableII
SelectiveInhibitorsofkinin-destr yingenzyme(Er otal,1963) Carboxypeptidaae-B pigancreas hippuryl-L-arginine 0
Enzyme Source Substrate EDTA DFP SBTI OTI Cysteine
€-amino-n-caproicacid 6murea MnCla C0CI2
(+=inhibition,0«noeffect-potentiatio ).Chymotrypsin pancreas 0 + ♦ +
♦ 0




T H E F U R IFICATIOW OF
BKADYKININOOEN BY
F K E G I Y I T A T I 0 N M E T H 0 D S
IWKQpunnop
Fractional precipitation methods have been
used in the purification of kininogens from
horse and ox blood (Henriquea et al, 1962j
Oreenbaum and Hosoda, 1963). These procedures
have the important advantage that they can be
applied to large volumes of plasma.
Three methods have been investigated.
1. fractional extraction with ammonium sulphate
solutions,
2. fractional precipitation with potassium
phosphate buffers, and
3. Cohn fractionation.
Each has failed to satisfy many of the criteria
listed in the introduction to this thesis,
THE FACTORS V^HICH DETERMINE THE SOLUBILITY OF A
PROTEIN.
The effect of salt concentration on the
solubility of a single protein was investigated
by Cohn* he derived the following expression,
hi
log.S = 0 - K . 1/2 (Cohn, 1925)
o
where S is the protein solubility in grams per
Kg, water, 1/2 is the ionic strength in moles
per Kg, water and K, and 0 are constants,
Dixon and Webb (1961) derived the modified
expression,
log.s = 0* - K*q. ^/2
where s is expressed in g/litre and X in moles/
litre of solution.
The intercept constant 0* is the theoretical
log. solubility in the absence of ealtj when
pH, temperature and dielectric constant are
controlled, it is characteristic of the protein.
K' is the "salting-out" constant - the
slope of the line relating log, solubility to
ionic strength. It is characteristic of the
protein-salt pair, and independent of pH and
temperature.
The importance of protein concentration
Salt may be added to a protein solution
without precipitation, until the protein
solubility no longer exceeds the protein
concentration. The solution Is then saturated
with protein and the lower precipitation limit
has been reached. This point is constant
U2
for s given protein only when its concentration
is constant,
Butler and Montgomery (1932) diluted plasma
"before precipitation to minimise protein
associations and co-precipitation, the evidence
for association in solutions of high ionic
strength is unconvincing however (Dixon and
I • •
! Webb, 1961), High dilutions not only reduce
the amount of protein which can be handled, but
also necessitate salt concentrations which
approach saturation and interfere with the
sedimentation of precipitates.
The choice of salt
When salt is added to the saturated protein
solution the solubility falls and protein
precipitates. The increase in salt concentration
for nearly complete precipitation is inversely
related to the slope of the log, solubility
curvet a high K' is required for narrow
o
precipitation limits and high resolution.
In experiments with csrboxyhaeiaoglobin the
K' values of common salts decreased in the order,
s
potassium phosphate, sodium sulphate, ammonium
sulphate, sodium citrate, magnesium sulphate,
U3
sodium chloride (Dixon and Webb, 1961),
Sodium sulphate has a low solubility relative
to ammonium sulphate and potassium phosphate
which were chosen for the experiments on human
bra&ykininogen.
The relative positions of the precipitation
limits of two proteins are altered by dilution*
they may be separated or approximated. The
effect of dilution can only be predicted if
K' is known for each protein.
Tfte of pH
A protein is least soluble at its
isoelectric point. In other parts of the pH
range a change of one unit may increase
solubility tenfold. The relative solubility
of two proteins with different isoelectric points
may be altered by a factor of several hundred.
The effect of temperature
0' varies inversely with temperature*
between 0° and 25° the solubility of
carboxyhaemoglobin falls by a fcctor of ten.
Ovalbumin has minimum solubility at 25° but this
is exceptional.
When designing a method other factors
influence the choice of temperature. The
solubility of the salt and the stability of the
protein must be considered.
Dielectric constant
Kthanol and acetone are extensively used in
the fractionation of plasma proteins (Askonas,
1951)• In their presence the dielectric
constant of the solution is reduced and protein
precipitates. These effects are opposed by
glycine.
Hgftvy
Metallic cations reduce protein solubility!
certain proteins form soluble complexes however.
Ammonium Bulphate is highly soluble and has
a moderate K' value. The risk of denaturation
s
is small and the salt makes certain dissolved
proteins more stable (Dixon and Webb, 1958).
When horse serum proteins were fractionated
by ammonium sulphate, the ionic strength was
increased slowly and smoothly by diffusion across
collodion membranes. The fractions were
classified by their behaviour on electrophoresis.
b3
Fractionation aUkgEfig. sepu^
(Cohn, McMeikin, Oncley, Newell arid Hughes, l9ho)
ammonium sulphate (moles/1) fraction
1,39 Y globulin
1.6h a,0 and y
globulins
2,05 &»£ globulins and
mucoproteins
2,57 albumin
2 , 80 a lbumin and
glycoproteins
(pH 6, room temperature)
Zahn and Stahl (1955) saturated human
plasma with solid ammonium sulphate. The
protein precipitate was mixed with kieselgur,
»»
supported in a Buchner funnel and extracted by an
ammonium sulphate solution of continuously
decreasing concentration, Several partially
purified fractions were resolved. The
effectiveness of the method was confirmed by the
separation of bovine serum albumin from human
haemoglobin (Zittle and Delia-Monica, 1955)*
Ammonium sulphate has no buffering capacity.
Different batches of commercial preparations
(Analar grade) give different pH values in
solution. The gloss electrode does not give
reliable readings in solutions above 0,3M
(Dixon and Webb, I96I).
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Fractionation with potassium ihoschate
Concentrated phosphate buffers are effective
precipitating agentsj the value of K' is high
D
and narrow precipitation limits can he obtained.
Cohn (1927) obtained data which made it possible
to prepare a series of potassium phosphate
buffers of constant pH but graded ionic strength.
Green and Hughes (1955) published such data in
tabular form.
Butler and Montgomery (1932) investigated
the solubility of plasma proteins in potassium
phosphate buffers at pH 6.5» Human plasma at a
dilution of Is 16 and 25° gave a complex
solubility curve with breaks in continuity at
1.1 and 2.UM. These points corresponded with
nearly complete precipitation of fibrinogen and
globulin respectively.
Fractional precipitation with potassium
phosphate buffers permits better control of
conditions than is possible with ammonium sulphate.
Fractionation with ethanol
During the early stages of development of
the Cohn procedures ammonium sulphate was
replaced by ethanol. Human p>lasma gave four
U7
fractions rich in fibrinogen, y globulin,
a.0 globulin and albumin, Denaturation was
minimised at 0° to -5° and the ethanol was
removed during freeze-drying (cohn, Leutscher,
Oncley, Armstrong and Davis, I9I+0). In I9U6
when "Method 6" was published six main fractions
and several subfractions had been obtained
(Cohn, Strong, Hughes, Mulford, /ahworth, Melin
and Taylor, I9U6),
"Method 10" was published in 1950j protein
fractions were precipitated close to their
isoelectric points under accurately controlled
conditions of temperature, pH, ionic strength,
dielectric constant and cation concentration.
Albumin (v), Y-glo^nlin (II) and fibrinogen (i)
were obtained in high purity. The more complex
fractions (ill) and (iv) were resolved into
multiple subfractions (Cohn, Gurd, Surgenor,
Barnes, Brown, Derouaux, Gillespie, Kahnt, Lever,
Liu, Mittleman, Mouton, Schmid and Uroma, 1950),
The occurrence of bovine bradykininogen in
IV-L. (method 6) and IV-6 (method 10) (van Arman,
19529 1955) has been described earlier.
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EXPERIMENTAL
FRACTIONAL EXTRACTION VvITH AMMONIUM SULPHATE
A simplified version of the fractional
extraction method of Zahn and Stahl (1955) ws 3
applied in the purification of bradykininogen.
It was hoped that kininogen would be extracted
after the removal of kallikrein or under
conditions in which kallikrein remained insoluble.
Loss of kininogen due to the action of kallikrein
would then be prevented.
The plasma globulins were precipitated in
3M ammonium sulphate at i+°. Protein fractions
were extracted from the precipitate by a series
of increasingly dilute solutions of ammonium
sulphate.
In small scale experiments the precipitate
was packed in the refrigerated centrifuge, drained
and re-suspended in the extracting solution.
In preparative experiments the extracting
solution was passed through a layer of precipitate
mixed with a filter-aid.
U9
Small scale experiment
1 ml aliquots of plasma were added to 3 ml
volumes of 4M ammonium sulphate. After 12 hours
at kG the precipitates were packed and each was
suspended in 5 ml of an ammonium sulphate
solution of known concentration. The
precipitate which remained after extraction for
one hour at was suspended in ethanol and the
bradykininogen content determined "by the method
of Orocklehurst and Lahiri (1962). The results
are tabulated below.







Most of the bradykinin precursor failed to
dissolve in 1.8M ammonium sulphate but little
remained insoluble at 1.0M.
Preparative experiment
20 ml plasma were added to 60 ml UM
ammonium sulphate at U°. After equilibration as
before the precipitate was mixed with 8 - 10 g
50
G-50 Sephadex and filtered under gravity in a
polythene Buchner funnel, A second filter paper
v/as applied after a firm layer had formed and the
precipitate was washed with 2.0M ammonium
sulphate. Six fractions were extracted in 100 ml
volumes, the concentration toeing reduced in 0.2M
steps. The bredykininogen content of each
fraction was estimated as before.








After 5 days in phosphate buffer at pH 7.6
and U° only the 1.2 M fraction contained more than
one unit of toredykininogen. The method appeared
to offer little prospect of kallikrein-free,
kininogen-rich fractions. Less than 20jj£ of the
toradykininogen contained in 20 ml of human plasma
(Diniz et al, 1961) was recovered.
Repeated attempts were made to increase the
yield of kininogen. The pH of the ammonium
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sulphate solutions was adjusted to 6.0 and 4.0
in different experiments end the protein
fractions were precipitated immediately after
extraction. There was little improvement
however and the method was not developed further.
FKACTIQflfih PfcBgiPITATSQN }OTA^CT FHPBfflATK
vvwrns
Potassium phosphate buffers were used in an
attempt to develop a fractionation method with
higher resolution and narrower precipitation
limits than those provided by ammonium sulphate.
Precipitations were carried out at pH 5.8
and 20°. pH 5»8 was chosen because this was the
pH for precipitation of IV-1+ (Cohn et al, I9U6)
and the presumed isoelectric point of the
bradykinin precursor. The poor solubility of
potassium phosphate at low temperatures made it
necessary to work at 20°. Plasma was diluted
1:11 to minimise co-precipitation.
Phosphate buffers of graded ionic strength
but constant pH were prepared according to the
data of Green and Hughes (1955) and Cohn (1927),
(Appendix 8 )• The molarities given below
take account of the dilution of buffer by plasma.
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Small pxpepllfieflt
1 ml aliquots of plasma were added to 10 ml
volumes of potassium phosphate "buffer; the
mixtures were shaken for 12 hours at 20°• The
bradykininogen contents of the precipitates were
determined after filtration.










,The first precipitation was carried out at
1.6 M, 50 ml of plasms having heen added to
500 ml 1.76 M "buffer, 3 hours were allowed for
equilibration, then the precipitate was removed
in a filter.
The filtrate was transferred to a dialysis
sac which was immersed in three volumes of 2.1+ M
buffer. 21+ hours were allowed for complete
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precipitation at the final molarity of 2.2.
Donnan effects and volume changes on mixing
were neglected.
The precipitate at 2.2 M contained 20 - hO
units bradykininogenj this represents about
of the theoretical yield predicted by the
small scale experiment. This loss was
attributed to the action of plasma kallikrein
which apparently remained active in 1.6 M
phosphate buffer at pH 5*8.
QQW IWCTOff iv-it
The specific activity of human IV-b
(Method 6) prepared from outdated acid-citrate-
dextrose blood was determined. Trypsin
released kinin equivalent to 0.06 ug
bradykinin from 1 rag of the freeze-dried
protein. The specific activity of total
plasma protein v/as 0.10 - 0.20 ug bradykinin/mg
protein* (Dinlz et al. 1961). Large losses
of kininogen had occurred during storage of
the blood or during the Cohn procedure.
IV-U was used in a preliminary experiment
with ion-exchange chromatogrsphy but it was
*A plasma protein concentration of 75 mg/ml
is assumed.
5U
not considered a suitable starting point for
further purification. IV-h from siliconed
fresh plasma was not available.
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Precipitation proe dures failed to resolve
kininogen and kallikrein, and serious loss of
kininogen thus occurred. It was therefore
decided to fractionate plasma by column
chromatography without preliminary purification.
THE COLUMN CHROMATOGRAPHY OF PROTEINS
Ion-exchange and adsorption chromatography
provide preparative methods with high resolution.
Ion-exchange on synthetic resins was
introduced as a means of separating fission
products and rare earth mixtures. The ions
penetrated the resin particles gaining access
to numerous exchange sites. (Spedding,
Fulmer, Butler and Powell, I950).
The weak cation-exchange resin, Amberlite
IRC-50, was used to separate stable proteins of
low molecular weight and high isoelectric point
(Zittle, 1953). Protein molecules did not
penetrate however and fine division of the
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particles was necessary to expose enough "binding
sites. This produced high resistance to flow.
Some proteins were "bound so firmly that the
molecules were distorted and the conditions
needed for elution caused denaturetion.
Calcium hydroxylapatite (Oa® (PO* JaOH) was
used in the fractionation of albumins, globulins
and other proteins (Tiselius, Kuerten, and Leven
1956). Columns have been used to purify plasma
kinin precursors (Habermann and Roseribusch, 1962}
Webster and Pierce, 1963). The exact nature of
the binding sites is unknown.
The introduction of cellulose adsorbents
was a major advance (Peterson and Sober, 1956).
They provided hydrophilic supports with large
surfaces for protein binding. Diethylaminoethyl
(DEAR-) cellulose and carboxymethyl (CM-)
cellulose were derived by substitution with
2-chlorotriethylamine hydrochloride and
chloroacetic acid respectively. DEAE-cellulose
had an anion capacity of 0.13 to I.98 mE/g and a
pK* of about 9.5 in 0.5 M NaCl. CM-cellulose
had a cation capacity of O.67 to 1.57 nd£/g and a
pK* between 3.8 and h.3 (Peterson and Sober,
1956).
DEAE- and CM- derivatives of the cross-
linked dextran gels, 0-25 and 0-50 Sephadex,
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became available during 1960/61. "DEAE-
Sephadex A-50w is penetrated by proteins
comparable in size to pepsin (35»000)* the
capacity for anion is 3 - h mE/g and the pK'
in 1 M KC1 about 8. CM-Sephadex C-50 has a
cation capacity of k - 5 mE/g and a pE* about
Under appropriate conditions the gel from
1 g of dry powder will bind 1 - 2 g protein.
The Sephadex ion-exchange derivatives are more
homogeneous than the corresponding cellulose
derivatives and have convenient handling
qualities.
Factors influencing adsorption
Binding occurs at pH values between the
isoelectric point of the protein and the pKf
of the ionising groups. The DEAE- derivatives
are effective below pH 8 and the CM- derivatives
above pH U. The affinity for the ionised groups
is determined by the number and distribution of
the charges on the protein molecule. A large
protein with s high charge density is most
firmly bound* high local concentrations of
charge favour binding.
The presence of electrolytes influences
protein adsorption* when the ionic strength
of the mediiim is moderate or high, the protein
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"binding capacity of the adsorbent is reduced or
abolished# The preparation of plasma protein
for adsorption commonly requires reduction of
ionic strength and pH adjustment# Vvhen the
initial adsorption is to be selective, the
adjustment must be exact* this may be
achieved by dilution, dialysis or gel-filtration#
Dilution is often satisfactory when the plasma
electrolyte composition is known. Dialysis is
slow. Dextran-gel filtration glvea rapid and
complete equilibration with buffer of chosen
pH and ionic strength, and will usually remove
some unwanted constituents concomitantly.
Protein is eluted when the association with
the binding sites is weakened by increased ionic
strength or pH change# Both of these variables
are used to obtain selective elution# This
should be achieved without recourse to extreme
conditions.
The conditions for high resolution are well
established (Peterson and Sober, 1962)# The
protein load should be small by comparison with
the total capacity of the column# The sample
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should "be applied in small volume or under
conditions which allow tight adsorption to
a long column of uniformly packed fine particles.
The ionic strength or pH should he altered in a
continuous gradient and not in discrete steps.
This takes full advantage of adsorption
equilibrium, the state in which partially
adsorbed protein moves slowly down the column.
Stepwise elution with a graded series of
buffers does not give high resolution but offers
advantages in other ways. Large loads may be
fractionated on short, wide columns with
coarse particles and high flow rates. Rapid
separation of components with different
adsorption characteristics occurs, e.g, an
enzyme may be separated from its substrate.
The fractionation of plasma proteins
The following examples of plasma protein
fractionation by column chromatography served
as a guide to the choice of conditions.
An inclusive fractionation scheme using
gradient elution from DEAJS-cellulose has been
described (Sober, Gutter, Wyckoff and Peterson,
1956), Selective elution was produced by
continuous increase in ionic strength and
60
decrease In pH; the proteins left the
column in decreasing order of isoelectric point.
The fractions were partly characterised by
paper electrophoresis; certain proteins were
identified more exactly. Proteins migrating
as cia globulins appeared in fractions 12 - 16
(gradient to 0.02 M NaCl, 0.05 M Nafta, PO*) and
again in fractions 21 - 29 (gradient to 0.10 M
NaCl, 0.05 U NaHaP0«). The fast aa component,
caeruloplesmin, appeared in fraction 28.
Albumin appeared throughout the latter half of
the chromatogram (15 - 30).
Human serum was fractionated on DBAE-
Sephadex A-25 equilibrated with 0.02 M
phosphate buffer pH 6.6. Elution was achieved
by stepwise increase in NaCl concentration.
(Lundbland, I962).
Hogmann and Killander (1962) separated
y-globulins on DEAE-Sephadex A-50 in phosphate
buffer at pH 8.0. The components of a plasma
protein fraction prepared by ^el-filtration were
resolved by gradient elution from DKAE— Sephadex
.at pH 8.0 (Gelotte, Flodin and Killander, I962).
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Flodin (1961) described the "behaviour of
human serum proteins on DEAE-Sephadex A-50 in
0.05 ^ phosphate "buffer, pH 6.6. Y-glo*>ulin and
a 0-coraponent were not adsorbed} albumin,
caeruloplaemin and the 19 S antibodies were
eluted by stepwise increase in NaCl concentration.
The non-adsorbed fraction was equilibrated with
O.Oh M acetate buffer, pH 5.8 and applied to
CM-Sephadex. Three y-globulins and transferrin
were eluted in separate peaks by increasing
concentrations of salt. Such a combination
of anion and cation-exchange steps has been
recommended by Peterson and Sober (1962).
/
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THE CHOICE OF ION-BXCHANGB MATERIAL
DKiUS-Sephadex became available shortly
before this work was started and it appeared
to have advantages over DEiUE-celluloBe.
Preliminary experiments with Cohn fraction
IV-U and diluted whole plasma suggested that
it could be useful in the purification of
bradykininogen.
75 mg IV-h (h«5 units bradykininogen) were
applied to a column of DKAE-Sephadex A-50
(l.3 x 20 cm) equilibrated with 0.01 M
phosphate buffer (pH 7.5* 0.02 M-NaCl). The
protein was eluted in 1 litre by continuous
increase in sodium chloride concentration.
Bradykininogen ( >3 unite) was eluted octween
sodium concentration limits of 0.16 and 0.28
E/l.
THE QF plab^ FOH WMM
It was found necessary to reduce the ionic
strength of plasma before chromatography.
Three methods of doing this were tried.
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i. EUatiaa
3 ml plasma were diluted to 20 ral with cold
0.02 M phosphate "buffer, pH 7*6 and applied to
a column of DEAE-Sephadex (2.4 x 10 era) at
4°. The salt concentration of the eluant was
increased in steps and five 250 ml fractions
were collected. The bradykininogen content of
each is shown below.
Fractionation of 3 ml plasma on DEAK-Senhadex MP
0.02 M sodium phosphate, pH 7.6, 4°.







The bradykinin precursor was adsorbed at
concentrations below 0.14 M but eluted when the
concentration was increased to 0.18 M.
20 ml plasma was added to a stirred
suspension of Dh^iS-Sephadex (12 g) in 180 ml
0.02 M phosphate buffer (0.08 M-NaCl) at 4°.
The suspension was filtered, packed into a
column and eluted as above. Bradykininogen
(18 unite) was eluted between 0.10 and 0.22M.
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In each, of these metnod© over 8Q& of the
klnin prectirsor was lost) the preparation of
plasma by dilution was therefore discontinued,
2. PWyglP
Human paeudoglobulin lost 9($ of its
kinlnogen during pressure dialysis at g
atmosphere and i+° for 21+ hours. No attempt
was made to prepare whole plasma for
chromatography by dialysis,
3. Gel-filtration
^sxtran gel columns separated potassium
phosphate from protein fractions with little
lost of kininogen. They were therefore used
to remove salt from plasma,
10 ml plasma was layered beneath buffer on
to a column of coarse <3-50 Sephadex (2,1+ x 15 cm)
equilibrated with 0,02 M phosphate buffer
(pH 7*35, 0,10 M-NaCl) at 3 - 5°. The column
was developed with the same buffer at a
pressure head of 20 - 30 cm, and a flow rate
of 90 ml/hour. The eluate was collected in
2,5 ml fractions. Optical density (X275 mu)
was taken as a measure of protein concentration
and specific conductivity (m,mho/cm) as a




measure of electrolyte concentration. The
elution pattern is shown in Figure I ;
in this experiment the salt concentration of the
plasma was increased tenfold "by the addition
of sodium chloride. The protein peak was
contained within the first 50 ml of eluate.
A gap of 7*5 ml separated this from the
beginning of the salt peak. The plasma was
equilibrated with phosphate buffer in 35 minutes,
(To avoid repetition the method described above
will be referred to as "Step I").
The loss of kininogen during Step I was
determined in a separate experiment. The first
50 ml of eluete was led into 200 ml ethanol.
The bradykininogen content of the precipitate
and of the original plasma was determined by the
method of Brocklehurst and Lahiri (1962).
Of the 118 units applied to the column, 98 were
recovered in the eluate (about 33^)• The yield
was reduced to 68 units when the column length
was increased to 25 cm. Free plasma kinin
was extracted by ethanol from the protein peak
( > 1.8 hg Bk) and from the salt peak
( > 2.0 jig Bk).
PLASMA
G-50 SEPHADEX





3-5 * 15 cms
FIG 2
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When 10 ml plasma was equilibrated with
0.02 M acetate buffer (pH 5.0, 0.10 M-NaCl)
the yield of kininogen (27 units) was not
improved. No free kinin was found in the
protein peak however (< 0.07 ug Bk) and the
equilibrated protein showed no further loss
of kininogen during 6 hours at U°.
The plasma kinin found in the electrolyte
peak was probably formed high up on the column
and separated from the protein by gel-
filtration. Plasma kaliikreinogen may have
been activated by dilution or contact with the
gel surface. The enzyme did not appear to
split the substrate at pH 5.0.
Dilution and delay during gel-filtration
were minimised by using the smallest adequate
column for each plasma volume. The
characteristics of the columns usee for
different volumes are given in the Appendix 10 .
The rapid transfer of equilibrated plasma to the
ion-exchange columns was achieved with © double
column (Figure 2 ). The upper G-50
Sephadex column was linked to the lower BKAE-
Sephadex column through a ground glass ;Jolnt.





The eluate from Step X was led on to a
column of DEAE-Sephadex A-50 (3.5 x 7»5 cm :
dry weight 5«7g) equilibrated with buffer "A"
(0.02 M sodium phosphate, 0,10 M sodium chloride,
pH 7.35)« The G-50 Sephadex column was removed
Immediately 50 ml of eluate had been transferred
to the lower column. In this way the salt peak
was prevented from interfering with the
adsorption of kininogen. The plasma proteins
were eluted from the DEAE-Sephadex column in
four main fractions, A,B, C and D by increasing
the sodium chloride concentration of the buffer.
Figure 3 is an elution diagram for this
column. The arrows mark the points at which more
concentrated buffers were applied. Fifty-five
20ml fractions were collected and the optical
density (X275 mu) of each recorded. The
quantity of klnin (ug Bk) in each alternate
fraction was assayed before and after incubation
with trypsin (200 ug/al, 37°# one minute)
Two optical density peaks appeared during
elution with buffer A, the first representing
non-adsorbed protein and the second protein in
adsorption equilibrium. A band of tightly
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adsorbed protein appeared as a "blue zone at the
top of the column# Free kinin (7«5 ug Bk) was
found in fraction 5» dust after the first
protein peak# The concentration of kinin in
fraction 5 fell rapidly at 37° and no additional
kinin was released by trypsin. Fractions 9 to
17 contained negligible quantities of kinin
(<0#2 ug Bk) even after incubation with trypsin.
Fractions 18 to 30 were eluted after the
sodium chloride coneentration had been raised
to 0.13 m (buffer b). The optical density
peak appeared in fractions 20 and 21 and the
blue band of adsorbed protein became more
diffuse but remained in the upper part of the
column. No free kinin (<0.10 ug Bk) was
detected in any fraction but kinin was released
"by trypsin from fraction-.:* 22 to 30> kininogen
appeared to be in adsorption equilibrium with
the cationic groups of the column at thiB salt
concentration.
Buffer C which had a sodium chloride
concentration of 0.16 M eluted a fourth optical
density peak which corresponded with maximum
kininogen activity. This elutlon coincided with
the disappearance of the blue band from the top
of the column. The elution of residual kininogen
continued in 0.18 m sodium chloride (buffer d).
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The effect of variation In Plasma volume
The total amount of klninogen eluted in
fraction C was measured in a aeries of
experiments in which different volumes of plasma
were applied to the DRAE-Sephadex column. In
each case the equilibration with buffer A was
carried out on the smallest adequate column of
G-50 Sephadex (see page 66 and Appendix 10 ).
The results are shown below.
The pf plagpa ?,oa4 qn j yfrqM
volume of plasma bradykininogen in fraction
(units)





10 ml plasma gave the highest absolute yield
and was used routinely in subsequent experiments.
The yield per ml plasma with a 5 ml load was
only slightly inferior.
The effpgt 9f„,variation In golWW l.ePfi.tfr
In later experiments the DEAE-Sephadex
column was lengthened (3.5 x 15 cm: dry weight
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This modification reduced the quantity of
kininogen eluted by 0.13 M salt so that the
kinin precursor was concentrated more
completely in fraction C. The elution pattern
for the longer column at a salt concentration of
0,16 M is shown in Figure 1+ • The position of
the optical density peak provided a guide to
the fractions containing most kinin precursor.
Table ni compares the results obtained with
the two column lengths. The distribution of
free kinin, kininogen and protein over the four
main fractions A,B,C and D is shown. Protein
concentrations were estimated by the modified
Folin method described in Appendix 5 .
The two sets of results are similar. In each
case free kinin was detected only in fraction Aj
this disappeared during incubation at 37° and no
further kinin was released by trypsin. The
kininogen was found mainly in fraction C
associated with about of the original protein.
The increase in length of the DKAE-Sephadex
column improved the specific activity of
fraction C from 0.9I to 1.3 \ig Bk/tig protein and
the yield of kininogen from 32 to The
preparation of fraction G on the modified column











































































The reproducibility of the method was
established by a series of experiments with
plasma from different donors. In these
experiments two measurements were made on each
main fraction, (a) the kinin (ug Bk) present
after 5 minutes at 37° and (b) the kinin (ug Bk)
present after incubation with trypsin for 5
minutes, (lGC$ kinin release by trypsin under
these conditions required less than 5 minutes.
See page 86), The full results end
calculations are given in Appendix 14 :
Figure 5 gives a graphical summary. Fraction
A consistently contained free kinin but no
kininogen, ( (a) and (b) did not differ
significantly). The free kinin in fractions B,
C and D was always below the tlireshold of the
biological assay (i.e. < 1.2 tig/fraction)•
Kininogen was regularly present in each of these
fractions but notably in fraction C.
(Note. More than a dozen DEAE-Sephadex
columns were run during the developmental stages
of the method. The results for eight of these
are tabulated in Appendix 13, Although the
same qualitative pattern occurs in each
experiment, the results have not been combined.
Quantitative differences were due to deliberate
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changes in the conditions.
The kininogen of fraction C was stable as a
freese-dried powder at 1+° for several months
and in solution at 37° for at least 2 hours.
The further purification of this preparation
of human bradykininogen is described in the
next chapter.
lh
T H K P U R I F I C A T ION 0_£




Electrophoresis in starch gel showed that
fraction C contained six or more proteins#
Some of these components appeared to differ
widely in molecular size (page 92) and gel-
filtration was therefore chosen as the method for
the further purification of kinlnogexi#
m of iimy-iKo w m-rmmm
The terms "gel-filtration" and "molecular
sieving" are applied to methods of fractionation
which depend upon the selective exclusion from
solvent spaces of molecules above a critical
size# Mould and Synge (195U) used collodion
membranes of graded pore size to fractionate
amyloses of different molecular weight#
Crystalline aluminosilicates with uniform pore
size have been used for the selective
adsorption of smell molecules (Hersh, I96I).
Before similar techniques could be applied to
the column chromatography of proteins it was
necessary to develop an hydrophilic gel with a
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uniform structure which would exclude only
proteins above a critical size. Deuel and
Neukora (195U) introduced a cross-linked
galactomannan and Porath and Plodin (1959) the
cross-linked dextrans with low water regain
(0-25 and 0-50 Sephadex). These provided rapid
and efficient means of separating proteins from
salts and small peptides but were of little
direct value in protein fractionation.
The fractionation of proteins was achieved
by gel-filtration on granules of 7% agar
(Poison, 1961), a polymer of acrylamide and
methylene bis-acrylsmide (Lea and. Sehon, 1962)
and cross-linked dextran gels of high water
regain (Gelotte, Flodin and Killander, 1962).
The latter have been made available commercially
aa G-100 and G-200 Sephadex} they are
synthesised from dextrans of selected length
by reaction with epichlorohydrin. The
practical and theoretical aspects of protein
fractionation on these gelB have been reviewed
in detail by Plodin (1962). Long columns of
fine particles offer high resolution when these
conditions are compatible with moderate flow
rates. High flow rates prevent the attainment
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of equilibrium at each level on the column
whereas low flow rates permit longitudinal
diffusion* In each case resolution is
impaired.
The behaviour of a protein during gel-
filtration is determined by its molecular
weight and its diffusion coefficient (Poison,
1961). There are several complicating
factors however. Proteins may be adsorbed
to Sephadex at low ionic strength (Glaser
and Wellner, 1962), fibrous proteins may fail
to penetrate the gel to the same extent as
globular proteins of the same molecular weight
and charged proteins within the gel may prevent
the entry of molecules carrying a similar
charge. Andrews and Polley (1963) calibrated
dextran gel columns with proteins of known
molecular weight. They found a linear
relationship between the log of the molecular
weight and the log* of the elution volume.
This relationship held for columns of G-200
Sephadex when the molecular weights were in
the range 20,000 - 500,000,
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Serum proteins were resolved into three
main fractions on G-200 Sephadex (Gelotte,
Flodin and Killander, 1962* Flodin and
Killander, 1962* Flodin, 1962), The first
contained proteins of very high molecular
weight which were almost totally excluded from
the gel (eta and fe macroglobullns and I9S
antibodies). The second consisted of an
intermediate group including 7S antibodies and
caeruloplasmin (mol, wt, 150,000) and the third
contained Beveral smaller proteins (albumin,
mol. wt, 66,000: haemoglobin mol.wt. 67,000:
transferrin mol, wt, 90,000: ©nd a,
glycoprotein). The pH of the buffer did not
affect the elution pattern but there was a
critical level for salt concentration*
below 0,10 M NaCl associations between proteins
impaired resolution. The bead form of the
gel was used successfully in columns up to
100 cm, long but other workers have found that
such columns became blocked due to the packing
of the gel under its own weight.
CHROMATOGRAPHY OF FRACTION C ON G-200
























THE CHROMATOGRAPHY OF FRACTION C ON G-200
sgipa^pfiX
Further purification of the bradykininogen
in fraction C was achieved by gel-filtration on
0-200 Sephadex. Fig 6 shows the elution
pattern of a gel column (2.1 x 9U.5 cm)
equilibrated with 0.02 M sodium phosphate
buffer (pH 7.35» 0.10 M NaCl) and loaded with
the freeze-dried protein and salt from 50ml
fraction C dissolved in 5.0 ml of distilled
water. The column was developed with 325ml
phosphate buffer at a hydrostatic pressure
of between 1 and 2 metres arranged to give a
flow of 7.5ml per hour. Fractions of 2.5ml
were collected and the optical density
( X 275 mu.) of each determined. The specific
conductivity was measured in fractions 92
to 133. Alternate fractions were incubated
with trypsin (60 37°» S minutes) and the
released kinin was assayed on the rat uterus.
The fractions corresponding with the first
half of the salt peak were assayed for free
kinin.
Fractions hO to 5h contained the main









CHROMATOGRAPHY OF FRACTION C




















occurred in fractions 54 to 66 and a third low
peak in fractions 66 to 80, Kininogen occurred
in all the fractions "between 40 and 80 hut the
activity was concentrated mainly in fractions
64 to 76. A small increase in kininogen
activity was found in 44 to 50* No free kinin
was detected (i.e. less than 0,025 ug Bk/
fraction).
Gel-filtration thus separated the hulk of
the kininogen from much of the other protein
present in fraction C without the release of
any detectable kinin during 40 hours at
18° - 20°, After three experiments on the
same column the maximum flow rate had fallen
to 2,5ml per hour and it was decided that
shorter columns would he more suitable for
repeated use.
Pig 7 shows the elutlon pattern obtained
when the kininogen from 90ml fraction G
(about 15 units) was applied to a shorter,
broader column (4.0 x 50 cms). This column
maintained a more suitable flow (30ml/hour)
and about 3($ of the kininogen was obtained in
fractions 128-156. Fractions 138 and 139
pooled had a specific activity of 5»2 ug Bk/mg
CHROMATOGRAPHY OF FRACTION C ON
G-200 SEPHADEX (2-1 * 42-5 cm )
FIG 8
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protein. In fractions 78, 82, 137 and lip.
parotid saliva (diluted 1:10) was used instead
of trypsin. The concentration of free kinln
was measured in fractions 80,92,102,111+, 126,131+#
11+2 and 151+j none was detected (i.e. less than
0.012 M-g Bk/fractlon). A column of this size
was mounted in a cold room at l+° and used
routinely in the preparation of purified
kininogen (Btep III). It was large enough
to receive the pooled fraction C from four
DEAE-Sephadex columns run concurrently.
qf iml<? strength
The small peak in kininogen activity during
the early pert of the elution was a constant
finding. Gel-filtration on a column of
G—200 Sephadex (2.1 x 1+2.5 cm) was repeated
under conditions of high ionic strength (0.5M
NaCl). There was little change in the elution
pattern (Fig 8 )• The small early peak
persisted under conditions in which the
liklihood of protein associations was small.
Summary
The purification of human hradykininogen "by
Steps I,II and III is summarised in table IV ;
the yield of kininogen and the specific activity
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Specific Biological Activity
Fractions 69 and 71 from the column of
0-200 Bephadex in the experiment illustrated in
Fig, 6 were each divided into aliquote.
Protein concentrations were determined by the
modified Folin method using crystalline bovine
serum albumin as a standard (Appendix 5 )
and the potential kinin was determined after
incubation with trypsin (10 ug/ml) for
5 minutes. Trypsin was inactivated by
heating at 100° for 10 minutes and the released
kinin was assayed against synthetic bradyklnin
on the rat uterus using a 2+ 1 dose design
(Appendix h )
Fraction specific activity
(mean & fiducial limits, P«0.05)
69 6,15 - 0,90 ug/ag
71 ^.89 - 0.53 ug/mg
Although the specific activity of the
purified kininogen was increased when fraction G
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was submitted, to gel-filtration, there appeared
to be no other change in pharmacological
properties.
Freedom from kinin-destro.vlng enzymes
Samples of fraction C from two experiments
were incubated with synthetic bradykinin.
After 2 hours at 35° the concentration of
bradykinin was compared with that of a solution
of bradykinin in saline which had received the
same treatment and another solution which had
been stored at 0°. The results showed no
evidence of kininase activity.
stability pf synthetic; ftrfidyfclnin J.n Fyactjjop Q.
t° O.g^ NaCl Fraction C bradykinin
(ng/nl at 2 hrs)
0 + - 12.5
35 * - 11.1
35 + 11.7
35 + 11.1
When the incubation of trypsin (10 ug/hil)
with Fraction C (600 ug/ml) was prolonged from
5 to 60 minutes, there was no evidence of
destruction of the kinin which had been released.
Similarly there was no loss of bradykinin-like
activity when the mixture of fraction C and
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parotid saliva was incubated for an additional
55 minutes#
Freedom from Plasma klnln
The samples of purified kininogen prepared
by step II and step III were repeatedly tested
for the presence of free kinin. In every case
the level lay below the threshold for the
biological assay* the uterus of the
stilboestrol-treated rat showed no response
either during contact with the sample or during
the wash which followed (Fig 9 ). In a
series of experiments the free kinin in
fraction C was less than 1.0 jig Bk whilst the
kinin released by trypsin was equivalent
to 47 - 9.3 dg Bk. (Fig 5 i Appendix 14 ).
Ppfteflpm Xsaa. JSJaXBc&IBlM. .fiflgyW
The absence of kinin-forming enzymes from
the preparations was inferred from the following
observations.
A solution of fraction C which was capable
of releasing 630 ng Bk/nl within 5 minutes of the
addition of trypsin (10 jig/ml) contained no
kinin (i.e. less than 17 ng Bk/fal) after
30 minutes at 371" •
I-O 0-5 ' O S " * l-o b-5
S S T T TJO 5 'I 5 30
RAT UTERUS .





S "Substrate blanks" Fraction G incubated
0 5 at 37° for ° and 5 minutes.'
Undiluted Dose 0.2 ml.
.
o /"\ Fraction C incubated with trypsin (601 . 5 » o U at 37° for 1, 5 and 30 minutes.
Diluted 1 : 20
Dose 0.10 ml.
Bp
Purified bradykininogen from 0-200 Sephadex
web exposed to acetone (20^ v/v) at 18° for
U hours; the acetone was then removed by freeze-
drying and the product was incubated with
fraction C for 5 minutes at 37° • No kinin was
released (i.e. less than 5 ng Bk/ral). Under the
same conditions parotid saliva (diluted 1 s 10)
released 130 ng Bk/fel in less than one minute.
No free kinin was released at any stage in
the gel-filtration of fraction C even when this
occupied UO hours at 18° - 20° (page 80).
Fraction C has been stored as a shell
frozen solution at -25° for b to 6 months
without the appearance of free kinin on thawing.
release pf Uhln
Trypsin During the early part of this work
trypsin was used at a concentration of
200 ug/fol for the release of kinin from fraction
C and similar preparations. This followed the
earlier practice of Diniz and Carvalho (1963).
Lahlri (1962) and others. Later it was
reduced to 60 ug/ml, and even at this level
it was usually found that full release of kinin
occurred during the first minute of incubation
(Fig. 9).
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A sample of fraction C with a protein
concentration of ahout 600 ug/ml was Incubated
with trypsin (10 ug/fal) at 37° • Allquots were
transferred to a "boiling water bath at
1,2,5 and 30 minutes. After heating for
10 minutes they were cooled and the kinin
released was assayed against synthetic
bradykininj 100^ kinin release waB achieved in
2 to 5 minutes. See table V »
Parotid saliva Human saliva obtained from the
parotid duct and diluted tenfold gave similar
results. Full kinin release occurred in less
than 5 minutes. The quantity of "bradykinin"
released appeared to be greater than with
trypsin. This may be due to differences in
the potencies of the kinine released by the two
enzymes.
Other enzymes Fraction C was incubated with a
sample of the kinin-forming enzyme (10 ug/ml)
purified from human plasma euglobulin by
Armstrong and Mills (l9&3)» After 30 minutes
at 37° about 2.5^ of the potential kinin had
been released and no further release was
detected at 60 minutes.
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Table V
2BKL.ag.1flvat4QP of EWE kAfllnogen by ftry,pgl;n
Ll9 yjfiM) Pflfl FargUfl 9flUya (Wytgd I lp lo)
bradykinin (ng/kl)
Incubation time (min) 1 2 5 30
Fraction C + trypsin 0.23 O.hk 0.63 0.63
Fraction C * parotid _ 0#69 0#69
Trypsin blank






Fraction 31 (figure 8)




In preliminary experiments no kinin
release from the purest kininogen fractions has
"been observed with acetone-treated fresh
plasma, diluted serum (l«20) and glass-activated
plasmaj in each case the plasma had been
depleted of its own kininogen by prolonged
incubation,
SfefiJtflaayLSg SL atoft kinto peleaged "by tr.ypgjp
The biological activity released by trypsin
from fraction C and from the purified kininogen
eluted from 0-200 Sephadex was bradykinin-like.
The rat uterus, the guinea-pig ileum and the
rat duodenum (Fig 10 ) responded in the same
way to synthetic bradykinin and to the product
of kininogen and trypsin.
Fraction 31 from a G-200 Sephadex column
(2,1 x U2,5 cm,) was incubated with trypsin
for 15 minutes. The concentration of kinin
was assayed on the rat uterus and the rat
duodenum (Fig, 10 ),
the parallel assay of the kinin
released b.v trypsin
assay klnln (ug synthetic Bk/ml.)
rat uteri's 0,8 -1,0
rat duodenum 0,8
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The bradykinin-like activity was stable
at 35® for 2 hours and at 100° for 15 minutes.
The incubation of fraction C with high
concentrations of trypsin (200 ug/tal) at
37° for 30 minutes (Pig, 9 ) resulted in
small, but consistent losses of up to
1C^ of the total kinin.
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PHYSICAL properties
The composition of' fraction C was
investigated "by electrophoresis in starch gel
using a small scale adaptation of the original
method (Smithies, 1955) (Appendix 17 )•
Starch gel was chosen because it was known that
cu> globulins were resolved into several
fractions during electrophoresis on this medium
and that the protein hands would he available for
elution, proteolysis and biological assay.
Samples of fraction C were concentrated
twenty-fold by pressure dialysis against 0.03M
borate buffer, pH 3.85» and placed in troughs
cut in the gel. After passing a current of
2,0 mA for 10 hours the gel was divided
longitudinally} half was stained with amido
black and the other half was divided transversely
into twelve £cm strips numbered from the origin.
Each strip was macerated in 3.0 ml 0.02M sodium
phosphate buffer, pH 7«35 and incubated with
trypsin (200 ug/ol, 37°» 15 minutes). The
kinin released was assayed against synthetic
bradykinin. The results are summarised in
Table VI • The kix.'nogen content of each strip
is noted and where possible the six protein
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bands are tentatively Identified, The
Identification is baaed on published information
(Smithies, 1959) and the observed behaviour of
whole plasma samples run parallel to fraction C
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A micromethod for Immunoelectrophoresis in
agar gel (Scheidegger, 1955) was used to
investigate the heterogeneity of the purified
bradykininogen.
Fraction C and the kininogen-containing
fractions from 0-200 Sephadex were concentrated
by dialysis followed by freeze-drylng. In each
case the dried protein from 25ml of eluate was
dissolved in 0.05ml 0.10M veronal acetate buffer,
pH 8.6 to give a protein concentration of about
50 mg/ml. These samples were compared with
each other and with whole serum by
immunoelectrophoresis against four anti-human
sera (institut Pasteur, 13U&1 and 223: Wellcome,
U505 and U506). The results are illustrated
by photographs of the slides taken under dark
ground illumination between 16 and 72 hours after
the addition of antiserum.
Slides 1.2 and 3 compare fraction C with whole
serum against Pasteur 223. Six components are
visible in slide 2 but eight or more arcs can be
seen in elides 1 and 3* The fastest component
of fraction C appears to be albumin. The
componenets which travel slowly during electro¬
phoresis and do not diffuse out from the
Pa ste u r
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longitudinal axle probably correspond with
the Scij and 0 lipoprotein zones on starch gel
electrophoresis.
Slides h and 5 compare purified bradykininogen
from G—200 Dephadex (2,1 x 9^,5 cm j fractions
63*65,67,73,75 and 77: Pig. 6 ) with whole
serum against Pasteur 223 and Wellcome h505«
Pour arcs are visible with each of the samples
of purified kininogen} the slowest component
which is absent from slides 6 and 7 may have been
introduced in fraction 63, which contains the
"tall* of the preceding optical density peak.
Slides 6 and 7 compare purified bradykininogen
from CJ—200 Sephadex (h,0 x 55 cm : fractions
127,130131,135,lU3,lU6,lh7,150,151 and 155:
Fig, 7 ) with whole serum against Fasteur 223»
The purified klninogen on slide 6 shows two
arcsf the faster of these links with the albumin
of whole serum. Slide 7 confirms the link with
albumin and shows two other componenti.
Slides a, 9 and 10 compare the sample of purified
kininogen used in 6 and 7 with fraction C
against Pasteur 223, On slide 8 a continuous
line links the albumin components of fraction C
and the more highly purified kininogen. Slide 9
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shows cross-over between the slower component
of the purified kininogen and a protein in
fraction C* Slide 10 shows three proteins in
the purified fraction* the slowest linking
with an arc in fraction C*
The most highly purified sample of
bradykinlnogen therefore contains at least
hree proteins* One of these is albumin
which was shown to have no kininogen activity
in the starch gel experiments* The remaining
two proteins behave as ol, globulins on
Immunoelectrophoresis but they have not
been identified more precisely.
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Rabbit y globulin, human kininogen, bovine
serum albumin and crystalline ovalbumin were
compared during gel-filtration on a column of
G—200 Sephadex (2.1 x h2.5cm) equilibrated with
0*50$ NaCl buffered at pH 7*1» In each
experiment the protein (5-12 mg) was dissolved
in 5»0 ml of buffer which was at least 1,0 M with
respect to NaCl, and layered on to the top of the
column. The positions of the optical density
peak ( A 275mu) (or the biological activity peak
in the case of kininogen) and the specific
conductivity peak were determined. The table vn
below gives the volumes of buffer required for
the elution of half the protein peak and half
the conductivity peak. The variability of the
latter is a measure of the failure to achieve
complete standardisation of the conditions.
The values for the molecular weight of the













The, ertutiorJli„.of.„huffla^i kfalflfigen, oth<gr
Pr.PtgjLns fppm Q-20Q Sepfradfts
buffer=0.02M sodium phosphate, pH7,10, 0.50M NaCl
uratein protein salt
(mol. weight) elu^ vo1* elUti(0S1)°:i"
rabbit y globulin 7?.,5 155
(160,000)
kininogen (donor l) 82.5 151







Figure 12 shows the curve obtained by
plotting log. elution volume against log.
molecular weight (Andrews and Folley, 1963).
The elution volumes for kininogen from donors 1
and 2 correspond with molecular weights of
106,000 and 9/4., 000 . (Donor 2 was of
haptoglobin type 2-2). The validity of these
estimates is criticised in the discussion.
98
DTPgUSSSPH
bcvclop-.-ent of a suitsale purification procedure
The protein precursor of the plasma kinins
is not detectable| its presence can only "be
inferred in retrospect after the "biologically
active peptides have been released by a
suitable enzyme. The enzyme chosen f'or this
purpose was trypsin. Partially purified
trypsin was available commercially and it was
known to release bredykinin from pseudoglobulin,
methionyllysylbradykinin and lysylbradykinin.
It was assumed that any protein precursor of the
three characterised kinins would give bradykinin
on incubation with trypsin. The precursors of
kinins E,P and S (Armstrong and Mills, I963) may
exist as distinct proteins which do not yield
their kinins with trypsin. If this is the
case the present investigation is not rele/ent
to these kininogens.
The kinin-fonaing pro-enzymes of plasma
remain inactive under a very narrow range of
physical conditions. Immediately a fraction¬
ation procedure is embarked upon, the plasma
bradykininogen is exposed to kinin-forming
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enzymes and It suffers progressive depletion
by kinin release. There are two ways of
avoiding this,
i. inactivatlon of the kinin-forming enzyme as
it is formed, and
ii. fractionation under physical conditions
which prevent enzymic activity.
■
Plasma kallikrein is inhibited by DFP,
soy bean trypsin inhibitor and pancreatic
-—trypsin inhibitor. kach might be used to
protect kininogen during the early stages of
purification. DPP does not prevent the
subsequent activation of kallikreinogen. It
would therefore be necessary to activate all the
-
proenzyme in the presence of DPP. The loss of
kininogen during this process might be
considerable. There is another objection to
DPP. It may combine with groups in the
kininogen molecule, serine units for example, and
alter the vulnerability of the protein to
physiological kinin-forming enzymes. Since the
main aim behind this work was the preparation
and identification of a physiological substrate
for kinin^-forming enzymes, any avoidable
alteration in the protein molecule was
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unacceptable, SBTI and PTI may have been
effective in reducing losses of kininogen "but
if any trace remained in the final product, it
could seriously interfere with later enzyme
studies.
It seemed wiser to accept the presence of
kinin-forming enzyme as inevitable during
the early stages and to operate under physical
conditions which were extreme enough to
discourage enzymic activity. Fractionation with
ethanol at -5° was a reasonable first choice but
facilities for low temperature work were not
available and the Oohn fractions available had
been prepared from outdated, kininogen-depleted
plasma. The results of Habermann (1963) and
his co-workers now suggest that further
exploitation of the Cohn methods would have
been profitable but at the time fractional
extraction with ammonium sulphate solutions at
*4.° seemed a practical alternative, Bradykinin-
ogen was known to be stable as an ammonium
sulphate precipitate and it was hoped that
suitable conditions might be found for the
extraction of kininogen and kinin-forming
enzyme in separate fractions. The resolution
was inadequate however and no kininogen-rich
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fraction was kallikrein-free# Potassium
phosphate "buffers offered better control of the
conditions which determined precipitation,
and adequate resolution was expected, Harrow
precipitation limits were established but big
losses of kininogen were still suffered.
The established methods for the
inactivation of interfering enzymes in plasma
were deliberately avoided because they seemed
to carry a serious risk of denaturation.
There was no advantage in obtaining a high
yield of kininogen if its characteristics had
been altered in the process.
The rapid equilibration of plasma with
acetate buffer at pH 5*0 was an attempt to
establish conditions which were unfavourable to
the kinin-forming enzymes of plasma but which
carried only a small risk of denaturation. The
kininogen in the eluate seemed stable but the
losses during the early stages of gel
filtration were discouraging, At this stage
it was decided to use an ion exchange method of
fractionation as the first purification step
hoping that it might be possible to separate
kinin-forming enzymes from kininogen before
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serious losses had "been sustained. After the
ionic strength of plasma had been lowered the
kinin precursor became tightly adsorbed to
DEAE-Sephadex. Large volumes of buffer could
be passed through the column and the bulk of the
unwanted protein eluted. The kininogen
.
remained firmly bound until the salt concentration,
of the buffer was increased. When this was
done the kininogen was eluted free from kinin-
conditions were adjusted until the best yield®
were obtained and an attempt was made to
increase the scale of the method. When larger
volumes of plasma were applied to the column,
the yield of kininogen was reduced. This was
attributed to the passing of kinin-forming
enzymes over the adsorbed kininogen for a longer
time.
The combination of Steps I and II gave
5C$ of the original kininogen in fraction C.
One may argue that the half lost wras different
from the half recovered in being more vulnerable
to the kinin-forming enzymes. A recovery
experiment with labelled kininogen would be
necessary to exclude selective loss. We know
that small changes in the method reduced the
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yield sharply. Increasing the length of the
0-50 Sephadex column reduced the yield from 5Oil
to 15^> and doubling the plasma load had a
similar efiect. We can therefore state that
the material we normally recover is very
readily attacked on the columns, and reasonably
assume that the unavoidable losses occur in this
way.
It has been implied above that the losses
of kininogen are the result of enzymic action
and not caused by the physical conditions used.
This assumption is supported by later
experience with fraction C. The kininogen
in this fraction is very stable. The losses
during storage and during prolonged chromato¬
graphic separations on G-200 Bephadex are small.
to aggessp^pt Qf
At the beginning of this thesis the criteria
of a satisfactory method were described. The
extent to which these have been realised will
now be considered.
1. "The purified bradykinln precursor shall be
free from kinin-forming enzymes and antagonists
of these enzymes and also from kinin-destroying
enzymes."
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Fraction G and the purified kininogen from
G-200 Sephadex are very vulnerable to trypsin
and to the kalllkrein of parotid saliva. Yet
there is no release of kinin when these
preparations are incubated alone at 37° for
2 hours. The preparations do not contain
enzymes like trypsin or salivary kallikrein.
They could however contain inactive kallilcreinogen
or a kallikrein which lacked an essential
cof*rctor. Attempts to demonstrate the former
by acetone activation failed, but the second
possibility is not excluded.
Trypsin and parotid saliva release the
potential kinin from fraction G and from the
kininogen eluted from G-200 Sejhadex very
rapidly even when the enzyme is highly diluted.
This suggests that the preparations are free
from enzyme antagonists but there is no
quantitative evidence to support this
suggestion.
The purest preparations of kininogen do
not increase the small loss of bradykinin
sustained during 2 hours at 37°• They are
kininase-free.
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2, "Conditions which carry a risk of
denaturation shall "be avoided,"
The risk of denaturation during the
preparation of fraction C is minimal. The low
temperature (3 - 5°) and the near physiological
buffer systems (pH 7*35 - 7*20j 0,10 - 0,16
M-NaCl) favour the preservation of the native
state. The most hazardous step is probably the
solution of^ the freeze-dried protein and buffer
salts prior to gel filtration on G-200
Sephadex,
3, "The purified protein shall retain its
biological activity under convenient storage
conditions for long periods,"
Experience with the most highly purified
fractions is still limited. Fraction C has
however been kept as a shell-frozen solution
and as a freeze-dried powder for six months
without serious loss of activity,
U» "A high proportion of the kinin precursor
present in fresh plasma shall be recovered,"
When 10 ml plasma are passed through steps
I, II and III, about of the original
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kininogen is obtained, in the final product
(table IV )« This is not good by absolute
standards but it compares favourably with the
other methods available for the purification of
plasma kininogen. Henriques et al (1962)
recovered 3*$ of the kininogen present in acid-
treated plasma but this figure takes no account
of the losses which accompanied acid treatment!
Greeribaura and Hosoda (1963) recovered less
than % of the kininogen present in the crude
globulin precipitatej Webster and Pierce
(1963) obtained 15% of the kininogen present
in outdated human plasma and Habermann and
Rosenbusch (1962) do not quote thellnr^ yield.
5* "The quantity of the purified kininogen shall
be adequate for the detailed study of the
activation by several enzyme systems and for the
preliminary characterisation of the protein.M
10 ml plasma yield about lOmg protein which
represents about 50 units of kininogen. The
sensitivity of the rat uterus is so great that
this corresponds with about 50,000 detectable
doses of bradykinin. The kininogen from 10 ml
plasma is therefore adequate for several
activation experiments), The small quantity of
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protein limits the "biochemical investigations
which are practicable.
6. "The final product shall he homogeneous
as Judged by a) protein fractionation
procedures with a high degree of resolution and
b) measurement of specific biological activity".
The final product is not homogeneous* It
contains albumin and at least two globulins.
It is possible that neither of these Is the
bradyklnln precursor. The antisera used in the
Immunoelectrophoresis were evoked by human sera
which probably contained no Intact kininogen.
The antisera may lack antibodies to human
brsdykininogen if the loss of kinin alters the
antigenicity of the parent molecule.
The specific activity of the most highly
purified samples of kininogen is about 6 u.g/mg.
This compares favourably with the values
obtained for other species by other groups. It
is inferior however to the values obtained by






(,ug Bk/ing of protein)
Henriques et al (1962) 3»1U (trypsin)
5,0 (snake venom)
(1962)
Greenbaum and Hosoda (I963)
Webster and Pierce (1963)
Haberaann and Rosenbusch 10 ~ 20
0,8 - 1,0
not given
If it is assumed that the molecular weight of
the human bradykinin precursor is about 100,000
and that one molecule of bradykinin (aol, wt.
1131) ie released per molecule of precursor,
it follows that 6 ug bradykinin are derived from
600 ug protein and that hC$ of the purified
protein is not kininogen.
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The physical nronerties of human brBdyklnlnogen
During electrophoresis in starch gel the
human brsdykinin precursor migrated as a fast
Oq globulin. This suggested thRt its
molecular weight was of the same order as
caeruloplasmln (snol. wt. 150,000). The
estimates of the molecular weight from the gel
filtration experiments were 9h,000 and 106,000
(figure 12). The behaviour of proteins during
gel filtration Is however influenced by factors
other than molecular weight. These may lead
either to under estimation or to over estimation.
Adsorption of kininogen to G-200 Sephadex
would lead to under estimation of its molecular
weight. The relevant experiments were
however carried out in 0.5M NaCl which makes
adsorption very unlikely. Premature elution
leading to exaggeration of the molecular weight
could be produced by association with other
proteins, deviation from a globular form or by
the presence of o large charge on the molecule.
The high salt concentration makes association
unlikely but the other factors can not be
excluded. The molecular weight probably li*s
between 160,000 and 65,000 but less confidence
can be placed in the lower limit.
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Ta.ftratofctatoQffin a fe s3Lsflfta3ia?
A number of proteins including brady¬
kininogen migrate as % globulins during paper
electrophoresis* Several of these are listed
below. Bradykininogen may be an unknown
protein or it may have been described in a
different context by workers who were concerned
with other properties and did not investigate
the peptides released by trypsin* There is a
third possibility* the kinin-depleted molecule
may have been Isolated independently and given
another name* This section deals with the
pertinent characteristics of several oq
globulins and examines the possibility that
each may be bradykininogen.
cu lipoprotein (0 lipoprotein, lipoeuglobulin)*
This protein which has a molecular weight of
about one million migrates very slowly in starch
gel (Smithies, 1959)* It is found in Cohn
fraction III-O and is most unlikely to be
the kinin precursor* The component of
fraction C which behaved like 0 lipoprotein in
starch gel had no biological activity
(figure 11, table VI).
Ill
a> macroKlobulln. This high molecular weight
a, glycoprotein was eluted in the first peak
from 0-200 Sephadex (Flodin and Killander, 1962)
and migrated to the SOj position in starch gel
(Smithies, 1959). This contrasts markedly with
the described behaviour of bradykininogen.
caerulonlasmln (copper combining globulin).
This protein migrates to the Faa position in
starch (Smithies, 1959) but is eluted from
G—200 Sephadex before the third peak (Flodin
and Killander, 1962). The blue zone on the
DEAE— Sephadex column ceased to be visible
tander the conditions which achieved the
elution of bradykininogen (page 68). Had the
two been identical however bradykininogen would
have been eluted from G-200 Sephadex in the
same fractions as rabbit gamma globulin
(mol. wt. 160,000).
haptoglobin. The haptoglobin in homozygous
subjects (l,l) closely resembles bradyklnlnogeni
it migrates as a fast Oj globulin in starch
(Smithies, 1959)» Has a molecular weight of
85,000 or 100,000 and is found in Cohn
fraction IV (Herman - Boussier, Cloorec and
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Cheftel, 1962). A similar protein is present
in the serum of heterozygous subjects (2,l)
in association with several different
haptoglobins. Homozygous subjects (2,2)
however do not have a haptoglobin with these
properties. Their haptoglobins behave like
larger molecules,
Brsdykininogen prepared from a homozygous
subject (2,2) was eluted from G-200 Sephadex
in the same position as the kinin precursor
from a donor of one of the other types (2,l)
(table VII), It is unlikely that brady-
kininogen is a haptoglobin,
Ojz globulin. This glycoprotein contains 10^
sugar and forms soluble complexes with zinc
(Hereraans, 1961). The description closely
resembles that of protein isolated by
teinbuch and Loeb (1961), The published data
about these proteins are not adequate for a
comparison with the known properties of human
bradykininogen.
/jre,..jy?pre KlntaQgeh®?
The behaviour of fraction C on G-200
Sephadex is shown in figures 6,7 and 8, In
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each case a staall peak in kininogen activity
coincides approximately with the first optical
density peak. The early kininogen peak is
more prominent in the columns eluted with "buffer
of low ionic strength (0.10M NaCl) but is still
present when 0.50 M NaCl is used.
The apparent separation of kininogen into
two components may be due to the association of
part with a larger protein or to the presence of
a second kininogen, perhaps a polymer of the
basic unit. The persistence of the early peak
in the presence of 0.5M NaCl suggests that an
association phenomenon is not responsible.
No other investigation provided definite
evidence for the existence of two different
kinlnogens in human plasma,
Purified bradykinlno«en as a substrate for
<a?-gw§.
The purified kininogen eluted from G-200
Sephadex released its potential kinin rapidly
in the presence of low concentrations of
trypsin or parotid saliva. The release of
kinin by trypsin was not prevented by 0.5M NaCl.
(0.20 M NaCl produced about 50% reduction in the
activity of trypsin on lactalbumin, Yon i960).
m
There was however no release of kinin by human
plasma or serum after a series of treatments
which are said to activate plasma kallikreinogen.
Only a few experiments of this type were
carried out and the significance of the results
is uncertain.
It is possible that the substrate for
plasma kallikreln is a labile kininogen which
has been lost during the purification procedure
but the results of Webster end Pierce (1963)
make this unlikely. The purified human
kininogen which they prepared released bredykinln
when incubated with a purified plasma kallikrein.
This kininogen represented less than 15& of the
kininogen present in outdated plasma.
The failure of treated plasma to release
kinin from purified bradykininogen may be due to
the presence of an antagonist in the plasma or
to the depletion of an essential cofactor like
the factor B described by Keele (i960).
The kinin-forming enzyme obtained from
human plasma euglobulln by Armstrong and Mills
(1963) was incubated with fraction C. Less
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than 2,5?£ of the potential kinin was released.
This enzyme was shown by Armstrong and Mills
to release not bradykinin but kinin E from
intact plasma. The kinin released by fraction
C may represent contamination of bradykininogen
with a small quantity of Hpro-kinin EH»
When trypsin acts on the purified human
bradykininogen the kinin released has the
pharmacological properties of bradykinin. The
results obtained by Webster and Pierce (1963)
suggest that it is bradykinin but parallel
bioassays, paper chromatography and electrophoresis
will be necessary before the identity is
established.
Tine study of kinin forming enzymes under
controlled conditions requires a substrate
which is free from kinin and the plasma enzymes
which release and inactivate kinin. If such
studies are to be relevant to the in vivo state
the substrate muBt resemble closely the
kininogen of circulating plasma i.e, the native
state of the protein must be preserved and the
yield of kininogen must be high. The method
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described in this thesis comes closer to
satisfying these requirements than the published
methods* It Is hoped that the purified human
bradykininogen so obtained will prove useful
in the investigation of kinln release in
physiological and pathological states*
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sVHMftRX
1, Unsuccessful attempts were made to purify
the bradykininogen* from human plasma by
fractional extraction with ammonium sulphate
solutions of decreasing ionic strength,
Fractionational precipitation with potassium
phosphate "buffers at pH 5*8 also proved
unsatisfactory. The heavy losses of
bradykininogen during these procedures were
attributed to the action of plasma kallikrein,
2, Plasms was prepared for chromatography by
gel filtration on 0-50 Sephadex (Step l)
without preliminary fractionation,
Bradykininogen became firmly adsorbed to
DEAB-Sephadex A 50 at a sodium chloride
concentration of 0,10M, A stable,
bradykininogen enriched fraction ("fraction
Cw) was eluted by stepwise increase in
sodium chloride concentration (step II),
3, A highly purified preparation of human
bradykininogen was obtained from fraction C
by gel filtration on 0-200 Sephadex (step III),
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The yield of bradykininogen and the
specific activity * of the protein fractions
at each stage in the purification procedure
are summarised in table IV (page 81)• The
yield was higher than that obtained with
any published method for the purification
of bradykininogen from plasma. The
specific activity of the final product waa
lower than that reported for ox bradykininogen
by Haberraann and Hosenbusch (1962) but
higher than the values obtained by other
workers. An important advantage in this
method is the absence of steps which carry
a risk of denaturation.
Human bradykininogen migrated as a fast
% globulin during electrophoresis in
starch gel. Comparison with reference
proteins on columns of G-200 Sephadex
indicated a molecular weight of 100,000.
Micro-Immunoelectrophoresis detected albumin
and two a? globulins in the purest
preparations.
The pxirifled bradykininogen was shown to be
free from kininase, plasma kinin and active
kinin forming enzymes. The "potential
bradykinin',JI was released rapidly by low
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concentrations of trypsin and "by parotid
salivs# Acetone treated plasma and a
purified kiriin forming enzyme from human
plasma euglobulin did not release the
potential bradykinin.
7. Purified human bradykininogen may prove a
useful substrate for the study of kinin
forming enzymes under the near physiological
conditions and for the detailed investigation
of the kinin forming system in human plasma.
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1* Collection of venous blood
aaiggjjifl
Inj* heparin B.P. 5,000 i.u./nl.





Blood was withdrawn from the antecuhital
vein through a wide bore needle and polythene
tube, into a siliconed, stoppered centrifuge
tube graduated at 25 ml. Rapid dispersion
of the anticoagulant (500 i.u. heparin in
0.5 ml. 0.95£ NaCl) was ensured by repeated
inversion of the tube. After spinning the
tubes at 2,000 g and 3-5° for 15 minutes in
a refrigerated centrifuge 10 ml. plasma were
withdrawn through a polythene tube into a
siliconed syringe lubricated with light
paraffin.
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Collection of parotid saliva
Uncontarninsted parotid saliva was
collected through a fine polythene catheter
which drained a perspex cup placed over the
ampulla of the parotid duct* The cup was
held securely against the "buccal mucosa by
applying gentle suction to an annular trough
cut around the cup in the perspex block.
Salivation was stimulated by applying citric
acid and sucrose to the back of the tongue.
12 i*
3. Estimation of Pie sina kininogen and free kinln
jjaateplftlS
Synthetic bradykinin (Sandoz, BR8 6hO
batch no. Oi+12).
lyophilized crystalline trypsin (Tryptarj




ethanol (distilled in glass over anhydrous
calcium chloride),
stilboestrol in arachis oil (100 ug/ml.)
BaU»a,Uofl ■ MBiB£E£R In 3tikMRS
0.2 ml. aliquots of plasma were ejected
rapidly from a blow out pipette into 5 ml.
8C?& ethanol at 0®. The suspended precipitate
was heated rapidly to 80-90° and held at that
temperature for 20 minutes. The suspension
was centrifuged and the ethanol removed by
Recantation. After washing in distilled
water the precipitate was suspended in 0.02 M
sodium phosphate buffer, pH 7»35» 0,10 M -
NaCl. Trypsin was added to give a final
concentration of 200 ug/ml, and the agitated
suspension incubated at 37° for 20 minutes.
The enzyme was then inactivated by heating at
100° for 10 minutes. The samples were then
frozen or assayed immediately.
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Estimation of klnlnoaen after ge1 filtration
The 50 ml, eluate from the G-50
Sephadex column was allowed to run directly
into 200 ml. absolute ethfsnol, The protein
suspension was mixed vigorously and 5 ml*
allquots were withdrawn rapidly. Each was
treated exactly as described above,
KgtfrnpUW 9l fcfotaPKfiP purified Samples
Protein fractions eluted from the DEAE-
and 0—200 Sephadex columns were incubated with
trypsin (60 or 10 ug/ml.) for 5 minutes unless
otherwise stated. No denaturation in
eth&nol was carried out. The fractions
produced by the precipitation and extraction
methods were however treated like whole
plasma.
Tfte e§tlpja,tlpp of fm? fl
Aliquots were heated to 100° for
10 minutes immediately after collection in
order to denature enzymes which might have
been able to release or inactivate kinin.
In a few experiments kinln w s extracted
in hot ethanol. The ethanol was removed
at h0° using a vacuum pump and capillary
leak.
126
The kinin released from whole plasma and
from the precipitation fractions was assayed
on the guinea pig ileum. The greater
sensitivity of the rat uterus was essential
for the examination of fractions from the
chromatographic experiments. The rat
duodenum was used to confirm that the kinin
released from the purified kininogen was
bradykinin-like, It was not used for routine
assay,
A piece of terminal guinea pig ileum
about 2 cm, long was suspended in a 2ml,
bath at 34° to 36°, The tissue was bathed
in oxygenated Tyrode solution, A frontal
writing lever with a six fold magnification
exerted a tension of 0,5 g on the tissue,
45 seconds contact between drug end tissue,
every 4 minutes was usually satisfactory,
Mepyramine maleate and atropine sulphate
(l ug/ial) were used to increase specificity.
Mi
Virgin, albino rats (l00~150g) were
given a subcutaneous injection of 10 « 15 ug
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stilboestrol in arachis oil, 18 - 20 hours
later they were killed and the uterine
horns excised,
A length of 1 - 2 cm, was suspended in a
1,5 ml, hath containing oxygenated de Jalon
solution with atropine sulphate (l ug/ml) at
29-31°• The recording lever described
above was used,
A sample was allowed to remain in
contact with the tissue for up to 2 minutes.
The cycle was repeated every six minutes.
The threshold concentration of brady-
kinin was commonly about 0,25 ng/ml. The
dose-response curve was steepj a
concentration of 1,0 an 1,5 ng/ml often
elicited a maximal response.
In the majority of experiments where
large numbers of fractions were being
screened, the assay was of a simple bracket
type. The calculations of the specific
activities of the most highly purified
preparations of kininogen were however based
on 2 + 1 dose assays and the calculation of




The first 2 - 3 cm of the duodenum was
suspended in oxygenated de Jalon at
29 - 31®• The fluid in the 2 ml. hath
was changed by overflow hut the flow was
stopped for up to 1 minute after the addition
of a sample. The frontal writing system
exerted a tension of 0.5 g and magnified
ahout ten fold.
A representative trace is shown in
figure 10.
129
4. Specimen of 2 + 1 dose assay
A sample of purified bradykininogen
(fraction 69, fig. 6 ) was incubated with
trypsin and the released kinin was assayed
on the rat uterus. The potency ratio and
its fiducial limits were calculated in the
way described by J.H, Gaddum (1953).
Pharmacol. Rev., £.»
preparation - rat uterus, de Jalon, 30®,
atropine sulphate 1 ug/nl.
standard - synthetic bradykinln.
(concentrations of 1.0 and
1.5 ng/ml.)
unknown - fraction 69 incubated with
trypsin and diluted 1 : 600
U =69/600 Si =1.0ng/ml Sa«1.5ng/ml (S=l,25ng/n3)
Results contraction height«y(rom) Zy* y*
S1 47 59 50 51 36 243 48.6
u 51 61 58 54 53 277 55.4
Sa 63 68 66 63 67 327 65.4
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Calculation of log potency ratio
yu = 55.ygi= U8.6j y^s 65.k (yg • 57)
E « "dose difference*1 « y - y m 16,8
B3 Si
I » log, ratio of doses » log 5*5. = 0,176
1.0
"b SS slope a E/I a 95.5
P « "preparation difference" « y - y « 1,6
D U
P
M « log, potency ratio = — = 0,0167
U ^
potency ratio » » l,0i*0
Us l.OUO x 1.25 ng/ml.
potential Taradykinin in fraction 69 = 600 U «
730ng/ral,
2Ty * 1*8,905
(Sy )2 * 717,uog
n » 15
Sv2 - (5JC)2
variance of y = ^ "n = 77
n - 1
variance of y = V = 22. - 5.13
n
variance of P « V™ » = 7.7F 2
variance of "b «■ ^ » 331
t (p » 0.05, n-1 = 12*) = 2.12*
fiducial limits of M » M ± Vp + \ M®
= O.OI67 - 0.0625
fiducial limits of potency ratio = 0.90 - 1.20
potential "bradykinin in fraction 69 »780ll20ng/iil.
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MpfrgurqBept of PPPteta <?oppeptrataop
The optical density at a wavelength of
275 mh was determined using a Unicam SP 500
Spectrophotometer, This was used as an
approximate measure of protein concentration.
More accurate determinations were made
by the method of Lowry, Rosehbrough, Parr and
Randall (1951) which uses the Folin,
Ciocalteau reagent. The reagent and sample
volumes were doubled to allow the use of
silica cuvettes with a 1 cm, light path.
No other modifications were made.
Standard calibration curves were
prepared with diluted normal human serum
assuming a protein concentration of 70 mg/fal.
This standard was used for the measurement
of protein concentrations in the fractions
fro the DEAE-Sephadex columns (table III ),
In later experiments with the purified
kininogen eluted from the <3-200 Sephadex
columns, bovine serum albumin was used as the
standard, A standard calibration curve
was determined with each new group of
measurements.
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Measurement of specific conductivity
All determinations were made on a
Philips conductivity bridge (type PR 9500)
at 1,000 c.p.e.
Approximate measurements for the
location of the electrolyte peak in the
eluate from a column were made at room
temperature using a micro-cell (constant =»
0,70).
Accurate measurements were made to
check the composition of the buffers used
in the stepwise elution of kinlnogen from
DEAK - Sephadex. For this purpose the
samples were "brought to 2$ 1 0.5° in a
water bath and larger cells were used
(constant * 1.33)»
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FRACTIONAL PRECIPITATION AKP EXTRACTIONS
7. aras.Uorwl i^traction witft amrnpyiium, p.^lpftal^
a<?3rttU9n§
The tables below summarise the results
of four experiments in which the purification
of bradykininogen was attempted by the
fractional extraction of plasma protein
precipitates.
experiment plasma volume jM
(ml)
(l) 10 6 20
(2) 10 6
(3) 20 6 U
U) 20 U k
smmXm sulphate
molee/l (units)
(1) (2) (3) (k)
1.8 3 12 U 6
1.6 12 27 16 6
l.U 10 10 10 6
1.2 5 12 5 10
1.0 < 2 9 < 1 <c h
0.8 mm <-1 < h
13U
3. Potassium phosphate Wers
Phosphate "buffers of constant pH (5*8)
"but graded ionic strength were prepared from
the data of Green and Hughes (1955)* The
composition of the buffers used in conjunction
with a plasma protein dilution of lill is
shown below.
A a initial potassium phosphate concentration
of buffer.
B « final concentration of potassium
phosphate after the addition of 1 vol.











1.5U 1.1+ 0,21+1+ 209 31+1
1.76 1.6 0.258 239 1+11+
1.98 1.8 0.269 269 kQk
2.20 2,0 0,280 299 560
2.1+2 2.2 0.290 329 638
2.61+ 2.U 0.300 359 71+0
2.86 2.6 0.310 389 807
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Cflfr riLVMFW OF pLAgllft
9* Gr59 Sephfid«» s ppepftr^lop paqfclPfl aP^
pe^pepat^pp
Coarse 0-50 Sephadex (water regain
5«0g/g dry gel: no 9860 c) was obtained from
A.B. Pharmacia (Uppsala). It was allowed
to swell in buffer for several hours. Fine
particles were removed by sucking off the
supernatant after the bulk of the particles
had settled. When this process had been
repeated several times the supernatant was
clear. The slurry was then exposed to low
pressures to remove dissolved air.
The delivery tube of the siliconed glass
column was packed with a skein of polythene
turnings and an extension tube was fitted to
the top. The slurry was poured and the
column packed in the way described by Flodin
(1962), The upper layer was stirred to
ensure a flat surface but no disc was added.
The plasma load was introduced through
a lntm. bore polythene catheter a few mm.
above the top of the gel. 10ml. of plasma
could be layered in this way within 5-10
minutes without disturbance of the gel or
mixing with the buffer.
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After use the column was dismantled and
the process of sedimentation in buffer
repeated. The gel was stored in 2M, salt
at 4°.
10• Column dimensions and characteristics
The table gives the characteristics of
the G-50 Sephadex columns used for the
equilibration of different volumes of plasma
with buffer. The excluded water voluran (Vo)
was determined from the position of the
optical density peak and the total water
volume (Vo + Vi) from the electrolyte peak.
££th dlS v° plasma o/eJiateuxoxucow applied collected
cm. cm. ml. ml. ml. ml.
45 2,4 55 170 30 100
25 2.4 35 95 20 80
15 2.4 20 58 10 50
10 1.3 8 23 5 18
137
mw mmw smmssmmx
11* Sodium phosphate buffers
The composition of the huffere used
for the fractionation of plasma on DEAE-
Sephadex is shown in Table VIII
12, ftKAE- S<3pHad^ac s preparation. packing and
sstfBms&iim'
DEAE- Sephadex, A-50 medium (water
regain » 5*0 g/g, anion capacity 3*5 ±
0.5 niE/g) was obtained from Pharmacia,
Samples from batches 787^ and 1602 were
used.
The gel was swollen, freed from fine
particles and freed from dissolved air in
the same way as the 0-50 Sephadex. The
slurry was poured anu ihe column packed.
Buffer was passed until the pH of the eluatc
was identical with that of the buffer
applied.
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After use the gel was transferred to
a no. 5U whatman filter paper in a B&chner
funnel. It was stirred with 2 volumes of
0.5 N. NaOH and then washed with distilled
water under suction. After stirring with
2 volumes 0.5 N.HC1. the gel was washed with
several litres of distilled water followed
"by buffer. This process appeared to produce
several fine particles but the subsequent
























































































































































































GEL FILTRATION OF FRACTION C
15. 0—200 Senhsdex : pre,para.U.<ffl» Packing anft
G-200 Sephadex (water regain 20.0g/g dry
gel: lot no. 64) was obtained from A.B.
Pharmacia, Uppsala.
The particles were allowed to swell
for at least 46 hours in distilled water
containing sodium chloride (shout 0.5M).
Particular care was taken during the
sedimentation in order to reduce the number
of fine particles to a minimum.
The columns were packed on top of a
support which consisted of cotton wool,
2mm, glass heads and coarse G-.50 Sephadex.
The top of the column was protected by a
filter disc and a 1 cm, layer of coarse G-50
Sephadex. These were necessary in order to
prevent loads of high specific gravity from
displacing loosely packed G-200 Sephadex.
Samples were loaded in the way
described for plasma.
Regeneration was carried out by reversing
the flow of buffer for several hours after




The following proteins were compared
with human kininogen on G-200 Sephadex.
twice crystallised ovalbumin (salt-free)
L« Light and Co., Colnbrook, England.
bovine serum albumin (fraction v) batch
CH 3170 Armour Pharmaceutical Co.
Ltd., Eastbourne, England.
rabbit gamma globulin (fraction II) lot 29.
Pentex Incorporated, Kankakee, Illinois, U.S.
Ikk.
rmmm QF pprmpp KWWW
17• Starch gel electrophoresis
materials
partially hydrolysed starch (Smithies)#
British Drug Houses# Ltd## Poole,
England,
potato starch, B#D#H,, Ltd#
low melting point paraffin (30 6#
white vaseline# 25ml, liquid paraffin#
25 ml, petrol ether)#
amido black in water : methanol : acetic
acid (5 1 5 : l).
methods
The method (Cruffc and Leaver, I96I) was
a small scale modification of the original,
(Smithies# 1955)» Starch gel was prepared
as described by Smithies and poured onto
thin glass plates# The gel was covered
with a polythene sheet and rolled flat#
The protein samples were mixed into a
paste with starch grains end placed in
troughs (o#l x 1#0 cm) cut in the gel#
Ik5
Evaporation was prevented by a coat of low
melting point paraffin. After passing
2 m.A. for 10 hours, the slides were
washed in petrol ether and stained with
amido black.
When trypsin incubation and biological
assay were performed the unstained gel was
divided by a vertical, longitudinal cut.
Before the two halves were separated a series
of transverse slits were made at £ cm.
intervals across the longitudinal cut.
In the half for bioassay the strips were
separated. After staining the other half
it was possible, despite shrinkage to




Agar (ionagar no, 2, Code no, L 12,
"batch 32, Oxo, Ltd,, London)
Veronal acetate "buffer 0,05 M, pH 8,6,




Horse antihuman serum, Wellcome, London,
lot U505
lot U506
The method of Scheidegger (1955) was
followed. Protein samples were dissolved
in 0,05M veronal acetate "buffer, pH 8,6
and pieced in circular wells cut in agar
gel on microscope slides, A current of
5 m.A, was passed for 1X hours and antiserum
was added to the troughs. The slides were
then observed during a period of 72 hours
at and photographed at suitable stages.
w
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